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ABSTRACT 
Headache is one of the most common medical complaints reported by individuals suffering from 
HIV/AIDS, but conflicting data exist regarding their prevalence, prototypical characteristics, and 
relationship to HIV severity. A well-established field of research indicates a strong association 
between psychiatric comorbidities/psychological factors and headache disorders, but this 
association has not been explored frequently among HIV patients with headaches. Data on 
headache symptoms and psychological factors were collected on 200 HIV/AIDS patients from 
two outpatient clinics using structured interviews and self-report measures. Of these, 107 patients 
(53.5%) endorsed problematic headaches, most of which (n = 103; 51.5%) were consistent with 
characteristics of primary headache disorders. Among those who met criteria for primary 
headaches, 88 (85.44%) met criteria for migraine, while 15 (14.56%) met criteria for tension-
type headache. Severity of HIV (as indicated by CD4 cell counts), but not duration of HIV, was 
strongly predictive of headache severity, frequency, and disability. Those with headache 
endorsed higher levels of comorbid depression, anxiety, and stress, as well as higher levels of 
pain catastrophizing, anxiety sensitivity, and fear of pain than did those without headache. These 
group differences were not attributable to differences in HIV duration, number of prescribed 
antiretroviral medications, or demographic differences such as age, gender, or race. The results 
indicate the presence of two distinct groups of individuals: one that is relatively healthy, both 
physically and emotionally without the presence of headaches or psychological dysfunction, and  
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one that is relatively unhealthy with frequent disabling headaches and comorbid psychological 
dysfunction. Implications for treatment and future research are discussed. 
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I. INTRODUCTION 
Headaches are the number one cause of medical complaints in the United States, 
accounting for approximately 10 million physician visits each year (The US Headache 
Consortium, 2000). Human Immunodeficiency Virus (HIV), the precursor to AIDS, has been 
consistently linked to frequent but varying headache patterns (Evers et al., 2000; Mirsattari, 
Power, & Nath, 1998). High rates of psychiatric comorbidity exist among both headache and 
HIV sufferers. As a consequence, the stress and emotional sequelae of headaches is highly 
problematic among the HIV population. Further research into psychiatric comorbidities and 
headache-related psychological factors could impact treatment planning and recommendations, 
in turn improving prognosis for HIV patients with headaches. The following text provides a 
detailed overview of the classification of headache disorders, and reviews the psychological 
factors associated with headaches (e.g., psychiatric comorbidities, cognitive factors such as 
anxiety sensitivity, fear of pain, and self-efficacy). The literature on HIV and HIV-related 
headaches, as well as that on psychological factors associated with HIV, is then reviewed. The 
goal of the current study was to determine the nature of headache patterns among HIV patients 
and the relationship of various psychological factors in their presentation.  
Headache Types and Psychiatric Comorbidities  
Classification of Headaches 
The Headache Classification Subcommittee of the International Headache Society (IHS, 
2004) classifies headaches into those that are “primary” and those that are secondary to another 
 2 
 
disorder. Primary headache disorders include the most common headache disorders such as 
migraines, tension-type headaches, cluster headaches, and other headaches not attributable to a 
secondary cause. Secondary headaches include those that result from other disorders or 
conditions known to cause headaches, such as those attributable to trauma, to vascular disorder, 
to substance use or withdrawal, to infection, or to a psychiatric disorder (IHS, 2004). Primary 
headaches are by far (90%) the most common category of headaches experienced by individuals 
who present to physicians for treatment (Saper, 1999). Although these categories of headaches 
are widely accepted across multiple disciplines, much controversy has surrounded their nature 
and classification (Holroyd, 2002).  
Migraine headaches affect nearly 12% of the United States population (Lipton, 
Hamelsky, & Stewart, 2001; Stewart, Lipton, Celentano, & Reed, 1992). Migraines typically last 
from 4 to 72 hours and are characterized as unilateral, pulsating headaches that are of moderate 
to severe intensity (IHS, 2004). They typically are aggravated by or cause avoidance of routine 
physical activities and are usually associated with nausea and/or vomiting, photophobia 
(sensitivity to light), and phonophobia (sensitivity to sound; IHS, 2004). Within the migraine 
category are two main types: migraine with aura and migraine without aura (IHS, 2004). “Aura” 
refers to the premonitory symptoms that may precede a migraine (i.e. typically visual or sensory 
disturbances such as flickering lights, spots, and tingling sensations), serving as warning signs 
that a migraine is soon to develop (IHS, 2004).  
In the United States, migraines are three times more common in females than in males 
(18% vs. 6%; Lawrence, 2004; Silberstein, Lipton, & Dodick, 2008). Unfortunately, although 
most migraineurs suffer from episodic attacks, some experience a more chronic form, 
characterized by 15 or more migraines per month, for at least 3 months (IHS, 2004). Despite its 
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episodic manifestations, recent research findings have contributed to a conceptualization of 
migraine as a chronic disorder associated with particular predisposing factors, abnormal cortical 
processing and trigeminovascular functioning, and an overall diminished quality of life 
(Ambrosini, Rossi, De Pasqua, Pierelli, & Schoenen, 2003; Gantenbein & Sandor, 2006; 
Granziera, DaSilva, Snyder, Tuch, & Hadjikhani, 2006).  
Overall quality of life and daily functioning are negatively impacted by migraines (Lipton 
& Bigal, 2005). Migraines are the direct cause of billions of dollars lost per year due to 
decreased work productivity, reduced work attendance, and related medical treatments 
(Lawrence, 2004). Frequency and intensity of attacks, combined with frequent psychiatric 
comorbidities such as depressive and anxiety disorders (Radat & Swendson, 2005), are also 
responsible for reduced quality of life seen in migraineurs.  
Tension-type headaches (TTH), the most common primary headaches (Rasmussen, 
Jensen, Schroll, & Oleson, 1991b; Schwartz, Stewart, Simon, & Lipton, 1998), cause mild to 
moderate pain as compared to migraines (IHS, 2004). TTHs are frequently described as the 
feeling of a tight band or belt around the head (Friedman, 1979). These headaches generally 
present bilaterally with a pressing, nonpulsating quality. Contrary to migraines, aura symptoms 
are absent and pain is not aggravated by routine physical activity (Rasmussen, Jensen, Schroll, & 
Oleson, 1991a). There are three sub-types of TTH: infrequent episodic, occurring less than 1 
time per month; frequent episodic, occurring from 1 to 14 times per month; and chronic, 
occurring 15 times or more per month (IHS, 2004). For chronic sufferers in particular, repeated 
TTHs sometimes intensify pain patterns, in which attacks may progress from moderate to more 
severe (Rasmussen et al., 1991a; Ulrich, Russell, Jensen, & Oleson, 1996; Scher, Lipton, & 
Stewart, 2003). 
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As is the case with migraines, TTHs are also the cause of reduced quality of life and 
disability. Particularly in chronic TTH sufferers, prevalence is highest during an individual’s 
most active years. Such high frequency can be the cause of much burden, impacting life 
personally, professionally, and socially (Lenaerts, 2006). To put the disabling effect into 
perspective, TTH is the cause of 820 lost workdays yearly per 1000 employees (Rasmussen, 
Jensen, Schroll, & Oleson, 1992).  
Cluster headaches (CH) are rare in comparison to migraine and TTH. CHs are 
characterized by severe unilateral pain, typically centered around and involving edema of the 
orbital socket, which usually peaks in the first 5 minutes and lasts, on average, for one hour 
(IHS, 2004). This type of headache causes so much distress that those suffering end up 
substantially exhausted after it has subsided (Dodick, Rozen, Goadsby, & Silberstein, 2000; 
Silberstein, Lipton, & Dodick, 2008). Due to the rarity of cluster headaches, the focus of the 
present study is primarily on headache patterns resembling migraine and TTH. 
Headaches and Psychiatric Comorbidity 
Not only are depression and anxiety potential causes of headaches (IHS, 1988, 2004; 
Breslau et al., 2000; Merikangas, Angst, & Isler, 1990), but long-term suffering with headache 
may place individuals at risk for subsequent psychological problems. Indeed, several studies 
confirm that individuals experiencing headaches are at a much higher likelihood of suffering 
from psychological problems than those without headaches. Saunders, Merikangas, Low, Von 
Korff, and Kessler (2008), in a study conducted using structured interviews for mood, anxiety, 
and substance use disorders on 5,692 members of the United States population, found that 83% 
of migraineurs and 79% of other headache sufferers reported some type of psychiatric 
comorbidity within the past 12 months. Jette, Patten, Williams, Werner, and Wiebe (2008) used 
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diagnostic interviews on 36,984 individuals to determine the prevalence of various psychiatric 
conditions in the presence of migraines. They found that major depressive disorder, bipolar 
disorder, panic disorder, and social phobia were two times more likely in individuals with 
migraines than those without. Given the high frequency of migraine and other headaches in the 
general population, the prevalence of psychiatric comorbidities among headache sufferers is 
quite alarming and worthy of continued study.  
Headaches and Depression 
The relationship between depression and headaches has been examined most frequently. 
Hamelsky and Lipton (2006) found that migraine sufferers are 2.2 to 4.0 times more likely to 
experience depression than the general population. Other studies have found that migraineurs are 
4 to 5 times more likely to experience depression, dysthymia, and bipolar disorder than those 
without headaches (Breslau, 1998; Lake, Rains, Penzien, & Lipchik, 2005). Saunders et al. 
(2008) found that 18% of migraineurs and 13% of other headache sufferers reported symptoms 
of major depression, compared to only 5.5% of non-headache sufferers. Most studies have found 
that the relationship between migraines and depression is bidirectional, with each disorder 
serving as a risk factor for the other (Breslau, Davis, Schultz, & Peterson, 1994; Breslau et al., 
2000; Breslau, Lipton, Stewart, Schultz, & Welch, 2003).  
Headaches and Anxiety 
Although the majority of research on psychiatric comorbidity and headache focused 
initially on depression, emerging research has confirmed that anxiety disorders are also uniquely 
prevalent among headache sufferers. Migraineurs are approximately five times more likely to 
suffer from an anxiety disorder than is the general population (Hamelsky & Lipton, 2006). 
Specifically, migraineurs are 3 to 10 times more likely to experience panic attacks, 4 to 5 times 
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more likely to receive a diagnosis of generalized anxiety disorder (GAD), and 5 times more 
likely to be diagnosed with obsessive-compulsive disorder  (Breslau, 1998; Lake et al., 2005; 
Breslau & Davis, 1993; Breslau, Schultz, Stewart, Lipton, & Welch, 2001; Maizels, Smitherman, 
& Penzien, 2006). Saunders et al. (2008) found at least one type of anxiety disorder in 44.5% of 
migraineurs and 30.9% of other headache sufferers, compared to only 15.5% of non-headache 
sufferers. Just as a bidirectional relationship has been observed between depression and 
migraine, a similar relationship is posited for headache sufferers with anxiety (Breslau et al., 
2001; Wang, Juang, Fuh, & Lu, 2007; Smitherman, Maizels, & Penzien, 2008; Baskin & 
Smitherman, 2009).  
Headaches and Substance Use Disorders 
In addition to elevated rates of depression and anxiety disorders, migraineurs have also 
been found to be two times more likely to suffer from drug, alcohol, and nicotine use disorders 
(Breslau, 1998; Lake et al., 2005). However, conflicting results have been obtained across 
studies. Jette et al. (2008) found that the incidence of drug and alcohol dependence in the 
migraine population (3.1% and 2.3%, respectively) was statistically similar to that of the general 
population (3.0% and 2.6%, respectively). Saunders et al. (2008) reported similar rates, with 
4.2% of migraineurs experiencing alcohol abuse/dependence and 2.3% experiencing drug 
abuse/dependence compared to 3.0% and 1.2% (respectively) of the non-headache population. 
Future research should help clarify which headache patients are at highest risk for substance use 
disorders. Table 1 summarizes the prevalence rates of various Axis I disorders and migraine, as 
reported in several large epidemiological studies. 
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Table 1  
 
Associations Between Migraine Headache and Axis I Psychiatric Disorders (in Odds Ratios 
[OR] adjusted for sex), as Reported in Five Major Epidemiological Studies 
           ___________ 
^Odds ratios adjusted also for age, ethnicity, employment, and education; *Odds ratios 
adjusted also for age; †Odds ratios adjusted also for age and education 
a
Odds ratios for Bipolar I or II was 3.9 in this study (not assessed separately) 
 
Negative Impact of Comorbid Psychiatric Disorders 
 
Psychiatric Diagnosis 
 
Breslau 
(1998), 
without 
aura 
 
Breslau 
(1998), 
with 
aura 
 
Breslau 
& 
Davis 
(1992) 
 
Saunders 
et al. 
(2008)
^ 
 
Swartz 
et al. 
(2000)
* 
 
Zwart et 
al. 
(2003)† 
 
Zwart et 
al. 
(2003)†, 
chronic 
migraine  
 
Major Depressive 
Disorder (MDD) 
 
2.2 
 
4.0 
 
4.2 
 
2.8 
 
2.25 
 
2.7 
 
6.4 
 
Bipolar I 
 
2.4 
 
7.3 
 
-- 
 
3.9
a 
 
-- 
 
-- 
 
-- 
 
Bipolar II  
 
2.5 
 
5.2 
 
-- 
 
3.9
a 
 
-- 
 
-- 
 
-- 
 
Panic Disorder 
 
3.0 
 
10.4 
 
6.0 
 
3.6 
 
3.40 
 
-- 
 
-- 
 
Generalized Anxiety 
Disorder  
 
5.5 
 
4.1 
 
5.1 
 
2.5 
 
-- 
 
-- 
 
-- 
 
Obsessive-
Compulsive Disorder 
(OCD) 
 
4.8 
 
5.0 
 
4.8 
 
-- 
 
1.32 
 
-- 
 
-- 
 
Phobia 
 
1.8 
 
2.9 
 
2.2 
 
2.6 
 
1.43 
 
-- 
 
-- 
 
Any Anxiety 
Disorder 
 
2.3 
 
3.1 
 
2.8 
 
3.1 
 
-- 
 
3.2 
 
6.9 
 
Alcohol 
Abuse/Depend. 
 
1.6 
 
2.1 
 
-- 
 
1.4 
 
1.05 
 
-- 
 
-- 
 
Illicit Drug 
Abuse/Depend. 
 
1.6 
 
3.9 
 
-- 
 
2.1 
 
1.05 
 
-- 
 
-- 
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Though many comorbidity studies have focused upon one specific comorbid disorder, 
depression and anxiety disorders often occur simultaneously in headache sufferers. Lanteri-
Minet, Radat, Chautart, and Lucas (2005) found that 19% of migraineurs experienced both 
anxiety and depression. Other studies have confirmed this shared comorbidity, finding that those 
with headaches are 2 to 5 times more likely to experience depression and anxiety than are those 
without headaches (Breslau, 1998; Lake et al., 2005; Hamelsky & Lipton, 2006; Guidetti et al., 
1998; Radat & Swendsen, 2005; Smitherman, Maizels, & Penzien, 2008).  
Although a majority of the psychiatric comorbidity research has focused upon 
migraineurs, those with other forms of headache, such as chronic daily headache or medication 
overuse headache, are at heightened risk as well (Baskin, Lipchik, & Smitherman, 2006). In fact, 
some have suggested that the risk for psychological problems is higher for those suffering from 
chronic daily headache or medication overuse headache than for migraineurs (Juang, Wang, Fuh, 
Lu, & Su, 2000; Verri et al., 1998; Lipchik, Smitherman, Penzien, & Holroyd, 2006), raising the 
possibility that comorbid psychiatric disorders may serve as one mechanism through which 
headache becomes chronic. Notably, elevated rates of psychiatric comorbidities occur also 
among TTH sufferers (Holroyd et al., 2000), who are more vulnerable to attacks when 
psychological factors such as depression and anxiety are present (Haythornthwaite, 1993).  
In addition to high prevalence rates of psychiatric disorders, the presence of psychiatric 
comorbidity is associated with multiple negative outcomes, foremost among them a poorer 
treatment prognosis. Psychological problems negatively impact headache treatment adherence 
and effectiveness, worsening overall prognosis for headache reduction and alleviation (Lake et 
al., 2005; Siniatchkin, Riabus, & Hasenbring, 1999). Guidetti et al. (1998), in a longitudinal 
study of 100 participants, found that of headache patients with two or more comorbid psychiatric 
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disorders in childhood or adolescence, 86% had either no improvement or worsening of 
headache symptoms at 8-year follow-up. By comparison, patients with no diagnosed psychiatric 
disorders experienced a remission of headaches after 8 years. The negative prognosis associated 
with comorbid psychiatric symptoms may in part be a function of patient adherence to their 
treatment regimens (Rains, Lipchik, & Penzien, 2006), such that patients with comorbid 
disorders are less likely to take their headache medication as prescribed. Thus, although the study 
sample sizes have not been very large, existing research evidence suggests that overall prognosis 
worsens in the combination of headaches and psychiatric disorders.  
In addition to poorer prognosis of headache, psychiatric comorbidities are associated also 
with lower satisfaction with headache treatment, increased headache-related disability, and 
overall reduced quality of life (Guidetti et al., 1998; Lanteri-Minet et al., 2005; Saunders et al., 
2008). Saunders et al. (2008) found that, during the last 30 days, migraineurs experienced role 
disability 25.2% of the time, compared with other headache sufferers and non-headache 
participants (17.6% and 9.7% of the time, respectively). Importantly, both migraine and non-
migraine headache sufferers with a comorbid psychiatric disorder experienced significantly more 
disability than their headache counterparts without a comorbid disorder. To put the added impact 
into a monetary perspective, migraineurs with both anxiety and depressive disorders spend 
$4,000 to $5,500 more on medical treatment each year than do migraineurs without a psychiatric 
comorbidity (Pesa & Lage, 2004).  
Headaches and Other Psychological Factors 
Headaches and Stress 
In addition to psychiatric comorbidities, other psychological factors have also been linked 
to the experience and exacerbation of headache. Among these are stress and negative cognitions 
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such as catastrophizing, anxiety sensitivity, and fear of pain (Holroyd et al., 1984; Holroyd et al., 
2000; Hudzynski & Levenson, 1985; Nicholson, Houle, Rhudy, & Norton, 2007; Nicholson, 
Nash, & Andrasik, 2005; Scharff, Turk, & Marcus, 1995; Maizels, Smitherman, & Penzien, 
2006; Houle & Nash, 2008). Assessment of these variables can be important in evaluating 
overall headache prognosis.  
Stress is an important determinant of an array of psychological and medical problems. 
Previous research has indicated that the frequency of stress in one’s life is directly related to both 
onset and exacerbation of headache (Holm, Holroyd, Hursey, & Penzien, 1986; Levor, Cohen, 
Naliboff, McArthur, & Heuser, 1986; Houle & Nash, 2008). Stress is the most commonly 
reported trigger of headaches (Rasmussen, 1993; Penzien, Rains, & Holroyd, 1993), and both 
migraineurs (Levor et al., 1986) and TTH sufferers (Holm et al., 1986) report a greater than usual 
frequency of stressful events prior to headache attacks. Stress has also been linked to headache 
chronification, or the progression of headache from an episodic to chronic form (Penzien, Rains, 
& Lipton, 2008; Bigal & Lipton, 2008; Scher, Midgette, & Lipton, 2008). 
Presently, the biological mechanisms behind the relationship between headache and 
stress remain largely unclear. Researchers speculate that stress impacts headache patterns by 
creating a higher sensitivity to environmental stimuli and a more arousable central nervous 
system (Drummond & Passchier, 2006). Waldie and Poulton (2002) speculate similar 
mechanisms linking headache and stress, describing an inheritance of heightened stress 
sensitivity in migraineurs to higher cortical arousal between headache attacks. Stress and 
emotional factors are speculated to impact headaches on both peripheral and central levels 
(Drummond & Passchier, 2006; Oleson & Goadsby, 2006). Peripherally, stress may be the cause 
of perivascular inflammation and pericranial muscle tenderness (Drummond & Passchier, 2006). 
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Centrally, stress may impact supraspinal control of neurons, increasing the excitability of 
trigeminal/spinal levels and decreasing effectiveness of the antinociceptive system (Oleson & 
Goadsby, 2006). Despite uncertainty surrounding specific biological mechanisms, it is clear that 
exposure to stress is associated with headache attacks, with increased stress leading to increased 
headache frequency (Houle & Nash, 2008).  
Cognitive Factors 
Catastrophizing 
As stress and pain interact, increased maladaptive reactions are expected. In chronic pain 
disorders, maladaptive cognitive responses often involve catastrophizing (Burns, Kubilus, 
Bruehl, Harden, & Lofland, 2003; Holroyd, Drew, Cottrell, Romanek, & Heh, 2007; Severeijns, 
Vlaeyen, van den Hout, & Weber, 2001; Sullivan et al., 2001). Catastrophizing involves 
distortion and overestimation of pain responses as well as underestimation of one's own ability to 
cope (Severeijns et al., 2001; Smitherman, Nicholson, Schafer, & Houle, in press; Sullivan et al., 
2001). Excessive rumination, pessimistic brooding, magnification, and spiraling feelings of 
helplessness characterize this negative cognitive style. Tsui, Thorn, Rubin, and Alexander 
(2007), in a study on 15 chronic pain patients, found that catastrophizing was positively 
associated with both self-reported pain (r=.91) and observed pain (r=.79). Behaviors related to 
catastrophizing impact accurate understanding of pain expression, which may affect both health 
care providers’ assessment and interpersonal social interactions regarding one’s pain (Tsui et al., 
2007). Although the topography and parameters of catastrophizing have yet to be studied much 
in the headache population, relationships between catastrophizing and pain in other chronic pain 
conditions (Burns et al., 2003; McCracken & Dhingra, 2002) underscore this topic as one worthy 
of exploration among headache patients.  
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Anxiety Sensitivity and Fear of Pain 
Other maladaptive cognitive responses to pain and pain-related stress have been studied 
more extensively in headache sufferers, among them the related concepts of anxiety sensitivity 
and fear of pain. Considered together, these two constructs underscore the notion that individuals 
suffering from chronic pain conditions are often hypervigilant toward and misinterpret particular 
bodily sensations. Anxiety sensitivity is a dispositional variable describing the fear of anxiety-
related symptoms due to beliefs about their presumed harmful consequences (Asmundson, 
Norton, & Norton, 1999; Reiss, 1991; Reiss & McNally, 1985). A person high on anxiety 
sensitivity, for instance, is overly attentive to somatic bodily sensations and often misinterprets 
such sensations as indicative of a more serious medical problem. Anxiety sensitivity engenders 
fear associated with anxiety, chronic pain, and other medical problems (Asmundson, Norton, & 
Norton, 1999).  
Anxiety sensitivity is thought to influence pain in two ways: 1) directly by strengthening 
fear-of-pain beliefs and 2) indirectly by contributing to pain-related escape and avoidance 
behaviors. Empirical studies have provided support for this model as it applies to migraineurs. 
Not only are high levels of anxiety sensitivity associated with increased depression and anxiety 
(Asmundson, Norton, & Norton, 1999), but anxiety sensitivity has been found to be the strongest 
psychological predictor of fear of pain, alone accounting for 39.8% of the variance in scores on 
measures assessing fear of pain among a sample of 72 adults with recurrent headaches 
(Asmundson, Norton, & Veloso, 1999). Anxiety sensitivity was a stronger predictor of pain-
related fear than was depression, state and trait anxiety, and headache severity scores.  
Fearing (McCracken, Zayfert, & Gross, 1992) and avoiding (Fordyce, 1976) pain have 
been associated with maintaining pain over time. Empirical studies have confirmed that fear of 
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pain is a stronger predictor of functional disability than is pain severity itself (McCracken et al.), 
suggesting that manifestations of fear of pain may be conceptualized as a phobic response that 
maintains pain and contributing behaviors. Fear of pain is closely linked to anxiety sensitivity. 
Norton and Asmundson (2004), in a structural-equation modeling study of 156 patients 
presenting to a neurology clinic (95% migraineurs), confirmed that anxiety sensitivity and 
severity of pain influenced fear of headache pain, which in turn contributed to resulting escape 
and avoidance behaviors. Consistent with the aforementioned model, headache severity (z = 
0.35) and anxiety sensitivity (z = 0.40) loaded significantly on fear of pain, which loaded directly 
on headache-related escape and avoidance behaviors (z = 0.90). In turn, headache severity and 
anxiety sensitivity both contributed indirectly to escape/avoidance behaviors via their influence 
on fear of pain. This relationship is depicted in Figure 1.  
Figure 1. Relationship between psychological variables associated with headache pain 
(as described by Norton & Asmundson, 2004) 
 The combination of avoiding and fearing pain creates a vicious cycle by which 
individuals’ inaccurate negative cognitions promote avoidance behaviors, leading to physical 
deconditioning and further increased pain, and, in turn, perpetuating avoidance (Asmundson, 
Headache 
Severity 
 
Fear of Pain 
Anxiety 
Sensitivity 
Pain-related 
Escape/ 
Avoidance 
.35 
 
.40 
.90 
.20 
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Norton, & Veloso, 1999; McCracken et al., 1992; Rachman & Arntz, 1991). This cycle 
contributes to maintenance of disability. Thus, anxiety sensitivity and fear of pain have important 
prognostic impact on coping with headache pain. 
 Headache Self-Efficacy 
  Effective self-management of headaches is a critical health adjustment variable and the 
primary goal of cognitive-behavioral approaches to treating headache disorders. Coping with 
headache-related pain involves interpreting and responding to a range of pain-related stimuli 
along multiple dimensions (Nash & Thebarge, 2006). In addition to the aforementioned cognitive 
variables associated with headache, self-efficacy has been identified as a crucial factor in 
headache control (French et al., 2000; Martin, Holroyd, & Penzien, 1990; McGrath, Penzien, & 
Rains, 2006). Bandura (1977) defined self-efficacy as "belief in one's capabilities to organize and 
execute the course of action required to produce given attainments" (p.3). In essence, self-
efficacy refers to one’s confidence or belief in his/her own ability to follow through with a 
particular course of action. Research indicates that high levels of self-efficacy are important 
factors in pain management, disability, and overall psychological functioning (Keefe et al., 1997; 
Lorig, Chastain, Ung, Shoor, & Holman, 1989; Spinhoven, Ter Kuile, Linssen, & Gazendam, 
1989).  
Changes in levels of self-efficacy moderate (Marlowe, 1998) and are correlated (Bond, 
Dirge, Rubingh, Durrant, & Baggaley, 2004) with the influence of stress on headache frequency. 
Self-efficacy also influences management of triggers, predicts response to treatment, and 
influences coping with pain (Anderson, Dowds, Pelletz, Edwards, & Peeters-Asdourian, 1995; 
Smith & Nicholson, 2006), such that higher levels of self-efficacy are associated with more 
favorable outcomes. In pain sufferers, self-efficacy can become enhanced through exposure to 
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feared activities without the pairing of negative consequences (i.e., experience of pain; Turk & 
Okifuji, 2002).  
Human Immunodeficiency Virus (HIV) 
Description of HIV/AIDS 
The human immunodeficiency virus (HIV) was first discovered in the United States as 
the primary cause of acquired immunodeficiency syndrome (AIDS; Clavel et al., 1986; Clavel et 
al., 1987; Kanki et al., 1987; Eickhoff, 1988). HIV attacks the body’s immune system by 
reducing CD4 white blood cells, disabling the body from fighting off illnesses (Center for 
Disease Control & Prevention (CDC), 2009). Once the body’s CD4 cell count falls below 200 
(per cubic millimeter of blood), a diagnosis of AIDS is warranted. During the early stages of 
HIV, most individuals remain asymptomatic. Those who exhibit signs typically display flu-like 
symptoms, such as fever, aching muscles, rash, and swollen glands (CDC, 2009). Without 
treatment, HIV usually progresses into AIDS within the first 8 to 10 years. With treatment, AIDS 
often can be held off for approximately fifteen years or more. In the later stages of HIV, before 
AIDS is diagnosed, more severe symptoms can include exhaustion, fever/night sweats, easy 
bruising, chronic yeast infections, thrush, significant weight loss, and chronic diarrhea. AIDS is 
commonly developed from opportunistic infections (i.e., tuberculosis, severe bacterial infections, 
lymphoma, recurrent pneumonia) that occur as HIV progresses (CDC, 2009).  
HIV/AIDS Statistics 
AIDS, first identified in the United States in 1981, had spread to 46,000 people by 1987 
(CDC, 1987) and was estimated to have infected one million people by 2007 (CDC, 2009; 
Martin, Fain, & Klotz, 2008). Worldwide, it was estimated that 38.6 million people were living 
with HIV in 2005 (Joint United Nations Programme on HIV/AIDS, 2008). The incidence of HIV 
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increased in the mid-1990s, declined slightly after 1999, and has been stable since then (Hall et 
al., 2008). Since its identification almost 30 years ago, HIV has persistently remained one of the 
greatest global public health challenges (CDC, 2009).  
HIV disproportionately affects males and those of minority status. In 2006, males made 
up 73% of the newly HIV-infected population, while females comprised only 27% (CDC, 2009). 
Of the newly infected, race splits were as follows: African Americans (45%), Caucasians (35%), 
Hispanics/Latinos (17%), Asians/Pacific Islanders (2%), and American Indians/Alaskan natives 
(1%; CDC, 2009; Hall et al., 2008).  
HIV-infected individuals were first identified within the homosexual male population 
(Eickhoff, 1988) and HIV and AIDS were first believed to be exclusively homosexual illnesses. 
As prevalence spread, though, the routes of contraction and primary populations at risk were 
accurately identified. Eickhoff (1988) reported that 65% of HIV-infected individuals were 
homosexual or bisexual males, 8% were homosexual or bisexual intravenous drug users, and 
16% were intravenous drug users only. From 2001 to 2006, 46% of new HIV-infections were 
among males who have sex with males (MSM; CDC, 2008). By 2006, 53% of new HIV-infected 
individuals were MSM (CDC, 2009). HIV can be contracted through sexual contact with an 
HIV-infected individual, needle sharing with intravenous drug users, birth to HIV mothers, and 
receiving multiple blood transfusions (Eickhoff). Fortunately, screening processes were quickly 
developed and implemented to prevent further HIV contraction from blood transfusions. 
Approximately 3 to 5% of HIV-infected individuals do not meet any of the aforementioned 
criteria, leaving a small window for unknown risk factors (Eickhoff). 
HIV was originally seen as a problem primarily for younger adults. However, estimates 
now indicate that 25% of the HIV population in the United States is 50 years and older 
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(Operskalski, Mosley, Busch, & Stram, 1997). From 2001 to 2005, the number of HIV cases in 
United States for people 50 years or older increased by 77% (Valenti, 2008). Given the lifelong 
struggle that most HIV-infected individuals endure, the cost of related medical care is expectedly 
high. Estimates have been made that lifetime health care costs for HIV-infected individuals range 
somewhere between $40,000 to $60,000 (Scitovsky & Rice, 1988). 
The death rates for older adults are higher than those for younger adults with HIV, and 
HIV progresses to AIDS more quickly in older adults than in younger adults. More than half of 
older adults develop AIDS within the first year of HIV infection (Martin et al., 2008). Research 
has indicated that only 59% of adults over 65 years of age survive past 36 months after 
developing AIDS, compared to 87-90% of adults aged 20-39 (Operskalski et al., 1997). 
Fortunately, through the development and widespread use of Antiretroviral (ARV) medications 
and the progressive Highly Active Antiretroviral Therapy (HAART), associated morbidity and 
mortality rates began to decrease substantially in the mid-1990s (Palella et al., 1998; Palella et 
al., 2006). Prognosis for HIV is currently considered as good or better than medical conditions 
such as hypertension and diabetes (Many, 2009), as it is now labeled more of a chronic than 
terminal illness (Gifford & Groessl, 2002). As stated by Vervoort et al. (2009), “Starting 
HAART is seen as a way to get control over HIV instead of being at the mercy of HIV” (p. 435). 
HIV and Psychiatric Comorbidity 
Along with the dramatic increase in medical problems and stigma related to HIV 
infection, the likelihood of experiencing mental illness is also much higher than in the general 
population (Acuff et al., 1999; Bing et al., 2001; Ickovics et al., 2001; Judd et al., 2005; 
Kemppainen, 2001; Sevard, Laberge, Gauthier, Ivers, & Bergeron, 1998). Living with 
HIV/AIDS is not easy. Those infected will encounter a variety of medical, social, and 
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interpersonal difficulties, typically resulting in considerable stress (Larya & Gien, 1993) and in 
turn occasioning psychological difficulties. According to the HIV Cost and Services Utilization 
Study (HCSUS), the first major research effort on people being treated for HIV infection, the 
prevalence of mental illness is significantly higher in the HIV population than the general 
population (Bing et al., 2001). In this study of 2,864 HIV-infected individuals, results indicated 
high prevalence rates of substance abuse disorders (50.1%), major depressive disorder (36.0%), 
dysthymia (26.5%), generalized anxiety disorder (15.8%), and panic disorder (10.5%; Bing et al., 
2001).  
HIV and Major Depressive Disorder. Depression is a particular problem among 
individuals living with HIV/AIDS. Acuff et al. (1999) conducted a large, multisite prevalence 
study and found that over 75% of HIV-infected individuals had major depressive disorder, 
dysthymia, or both. Using structured diagnostic interviews and self-report measures on 129 
HIV/AIDS patients, Judd et al. (2005) found that 27% met criteria for a mood disorder. Using 
self-report data, Sevard et al. (1998) found that one-fifth of 149 HIV participants described 
symptoms of depression. Thus, while exact prevalence rates of depression have varied 
considerably depending upon the study design and method of assessment, these disparate studies 
all confirm very high rates of depression among the HIV/AIDS population. 
Treisman, Fishman, Schwartz, Hutton, & Lyketsos (1998) described two different types 
of depression in the HIV population: primary and secondary. Primary depressed individuals are 
those with causes similar to the general population (i.e. family history of mood disorders, 
personality disorders, and experiences of adverse life events). Secondary depression occurs in 
those who are suffering from depression as a result of living with HIV/AIDS (Treisman et al., 
1998). By contrast, Judd et al. (2005) found no distinct subtype of depression in HIV patients. 
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Their findings indicated that depressed HIV individuals were within the range of well-recognized 
risk factors for depression and that social support was among the most important protective 
factors. However, research has yet to find definitive evidence to describe the typical expression 
of depression in HIV/AIDS.  
The implications of high psychiatric comorbidity in the HIV population are alarming, as 
depression has harmful negative effects on overall HIV prognosis. The presence of major 
depressive disorder in an HIV-infected individual not only reduces quality of life, but also 
reduces adherence to ARVs (Kemppainen, 2001) and results in increased mortality (Ickovics et 
al., 2001). With the more severely depressed HIV patient, an associated increase in functional 
impairment likely exacerbates disability, highlighting a need for early diagnosis and intervention 
(Judd et al., 2005). 
Due to the negative implications of psychiatric comorbidity among HIV patients, 
accurate screening for depression is crucial. Somatic complaints are included on many 
depression measures, but their presence can often obscure the diagnostic picture when assessing 
individuals with chronic medical conditions such as HIV or AIDS. Therefore, the most useful 
tools for measuring depression in this population are those in which somatic questions have been 
excluded (Cavanaugh, Clark, & Gibbons, 1983; Clark, Cavanaugh, & Gibbons, 1983), such as 
the Depression, Anxiety, and Stress Scale (DASS; Lovibond & Lovibond, 1995), the BDI-Fast 
Screen (Beck, Steer, & Brown, 2000), or the POMS Depressive-Dejection subscale (Patterson et 
al., 2006).  
HIV and Other Psychiatric Comorbidities. In addition to depression, anxiety has also 
been a focus in HIV research. Although virtually all studies have indicated a high prevalence of 
anxiety disorders in HIV-infected individuals, reported prevalence rates have varied from nearly 
 20 
 
half (Sevard et al., 1998) to 70% (Cohen et al., 2002). Hintze, Templer, and Cappelletty (1993) 
found that family or partner knowledge of an individual’s HIV diagnosis positively correlated 
with anxiety about death. Thus, HIV appears strongly associated with persistent worrying, 
including fears of mortality.  
Substance abuse is also highly prevalent among individuals with HIV/AIDS. 
Kemppainen et al. (2006), in a study of 502 HIV-infected individuals, found high prevalence of 
current or past IV drug use (40%) and use of alcohol (45%), marijuana (25%), and cocaine 
(20%). Pence, Miller, Whetten, Eron, and Gaines (2006) found that alcohol- and drug-related 
disorders were significantly more likely among HIV clinic patients than among the general 
population (2.5 times and 7.5 times more common, respectively). One can assume that 
significant substance abuse and other comorbid disorders in the context of HIV will only 
exacerbate symptoms and worsen prognosis. 
Researching HIV psychiatric comorbidity provides important information to health care 
providers about providing optimal continuity of care. Not only does it highlight the need for use 
of psychometrically validated tools by medical health providers, but assessing psychiatric 
comorbidities also underscores the need for referrals to mental health providers. Neglecting to 
screen for mental illness or to recommend a psychological consult could make a significant 
difference in overall prognosis. 
HIV and Headaches 
Headache in the HIV Population 
Headaches are one of the most common medical complaints in the HIV population 
(Graham & Wippold, 2001; Holloway & Kieburtz, 1995; Newton, 1995). The potential for 
headache susceptibility is increased in this population due to a higher likelihood of head-pain-
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related complications such as meningitis, sinusitis, or neurosyphilis (Wilson & Sande, 2001). 
Studies have found the prevalence of headaches in the HIV population to range from 40% 
(Mathews et al., 2000) to 61% (Justice, Rabeneck, Hays, Wu, & Bozzette, 1999). However, 
previous research has been unable to pinpoint a “typical” HIV headache, with considerable 
variability of headache patterns reported by HIV-infected individuals (Marchioni et al., 2006). 
One study found that TTH was considerably more prevalent than migraine (46% vs. 16%, 
respectively) and other headache types (6%; Evers et al., 2000), while another reported that 
migraines were more than five times more common than TTH and cluster headaches (76% vs. 
14% vs. 10%, respectively; Mirsattari, Power, & Nath, 1998). No specific marker has been found 
for headache onset in HIV progression either, with headaches occurring both at various points 
throughout the course of HIV and after AIDS has developed (Holloway & Kieburtz, 1995; 
Singer, Kim, Fahy-Chandon, Datt, & Tourtellotte, 1996). However, some evidence suggests that 
as HIV progresses, migraine frequency decreases, while TTH frequency significantly increases 
(Evers et al., 2000).  
The varied headache manifestations and course of headaches in HIV patients underscore 
the notion that accurate diagnosis of the HIV headache is challenging. In addition to primary 
headaches that occur in conjunction with (but are not caused by) HIV, it is now well recognized 
that some headaches in HIV patients are directly attributed to the HIV/AIDS infection itself (IHS 
code 9.3, “Headache Attributed to HIV/AIDS”). Generally, three patterns of headache 
attributable to HIV have been described. The first, consisting of a dull, continuous headache 
without consistent descriptions of duration, site, and response to medication, is a direct symptom 
of HIV infection (IHS, 2004; Holloway & Kieburtz, 1995; Marchioni et al., 2006). The second 
pattern is related to the contraction of aseptic meningitis, a rare development that can appear 
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during different stages of HIV (IHS; Holloway & Kieburtz; Marchioni et al.). The third is a 
pattern of headache related to the variety of opportunistic encephalic infections (i.e. tuberculosis, 
severe bacterial infections, lymphoma, recurrent pneumonia; CDC, 2009) that can occur 
throughout the course of HIV (IHS; Marchioni et al.). Diagnosis of the latter two patterns can be 
impaired by high costs of medical procedures needed to confirm the diagnosis. When meningitis 
or other encephalic infections are suspected, defensive medical assessment practices, such as 
lumbar punctures, MRIs, and CT scans, are implemented (Many, 2009). Further research on the 
HIV headache could potentially reduce the need for using these expensive and sometimes 
unnecessary procedures, cutting overall medical costs drastically.  
Beyond the aforementioned headache types in the HIV patient, headaches due to 
medication side effects have been discussed on a limited basis. Headaches sometimes occur as a 
side effect to HIV medication (Hervey & Perry, 2000; Cvetkovic & Goa, 2003), but findings are 
not consistent and are thus not included in IHS classification criteria (IHS, 2004; Holloway & 
Kieburtz, 1995). More severe HIV headaches often appear related to causes such as mass lesions 
and medication side effects, among other causes (Newton, 1995).  
Current Study 
As has been illustrated, confusion surrounds the epidemiology and nature of headache 
patterns in the HIV population, warranting further research in this area. Marchioni et al. (2006) 
called for further reassessment of the HIV headache, concluding that a definite diagnosis of 
exclusion would be helpful for treatment considerations. At present, the literature does not 
provide enough evidence to distinguish HIV-related headaches from headaches not directly 
related to the infection (Marchioni et al., 2006). The results of the present study will provide 
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much-needed information about headache symptoms and patterns among HIV patients at varying 
stages of the HIV or AIDS disease process.  
Extant literature has consistently confirmed both high prevalence of headaches in the 
HIV/AIDS population and elevated rates of psychiatric comorbidities among headache sufferers 
and individuals with HIV/AIDS. This literature has confirmed also that such comorbidities and 
other associated psychological factors are significant predictors of headache-related variables 
and prognosis. However, there is a strong need for extending these findings on the importance of 
psychological variables to individuals with headache in the HIV/AIDS population.  
Therein lie the goals of the present study, which were designed to inform existing gaps in 
the literature on headaches among individuals with HIV/AIDS. The present study was designed 
to 1) determine headache patterns characteristic of those with HIV/AIDS; 2) explore levels of 
comorbid psychiatric symptoms between HIV patients with and without headache; and 3) 
determine the relationship between psychological variables (e.g., stress, self-efficacy, cognitive 
factors such as catastrophizing, anxiety sensitivity, and fear of pain) and headache characteristics 
among those with HIV/AIDS. The study was designed with the applied goals of facilitating 
recognition of headache characteristics among HIV patients and identifying relevant 
psychological factors that merit clinical attention in order to improve treatment outcomes. 
The following goals and hypotheses were proposed: 
Study Goal 1: Description of headache symptoms in HIV patients 
Hypothesis 1a: Headache frequency, severity, and disability will increase as CD4 counts 
decrease and years living with HIV increases.  
Hypothesis 1b: Increased relative prevalence of TTH symptoms (vs. migraine symptoms) will be 
associated with decreased CD4 counts and longer duration of HIV. 
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Hypothesis 1c: Individuals with preexisting headaches (prior to HIV contraction) will report 
increased frequency and intensity of headaches since acquiring HIV. 
Hypothesis 1d: Headaches characterized by a dull, bilateral ache (IHS code 9.3) will be more 
prevalent among HIV/AIDS patients than migraine and TTH.  
Study Goal 2: Group differences on psychiatric symptoms and psychological variables between 
headache and non-headache HIV patients 
Hypothesis 2a: Psychiatric Symptoms: HIV patients with headache will report higher levels of 
depression, anxiety, and stress compared to HIV patients without headache. 
Hypothesis 2b: Psychological Variables: HIV headache patients will report higher levels of 
catastrophizing, anxiety sensitivity, and fear of pain than will their non-headache HIV 
counterparts. 
Hypothesis 2c: HIV headache patients will report higher levels of anxiety sensitivity pertaining 
to physical concerns than will HIV patients without headaches. 
Study Goal 3: Determine prediction of headache-related disability and severity afforded by 
psychological (cognitive) variables. Psychological Variables will predict levels of headache-
related disability and severity, even after controlling for levels of depression and anxiety. 
Hypothesis 3a: A regression model comprised of 1) demographic factors and 2) depression and 
anxiety scores will be significant predictors of headache-related disability and severity. 
Hypothesis 3b: Psychological variables including levels of headache self-efficacy, 
catastrophizing, fear of pain, and anxiety sensitivity will offer incremental prediction of 
headache-related disability and severity (i.e., above and beyond that afforded by demographic 
variables, CD4 counts, and levels of comorbid depression and anxiety.). 
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II. METHOD 
Study Sites and Participants 
Participants were patients diagnosed with HIV or AIDS presenting to two clinics in 
Montgomery, AL: the UAB Health Center Montgomery Internal Medicine Residency Program 
and the Montgomery AIDS Outreach (MAO) Program. Recent reports indicate that Montgomery 
County has the highest per capita rate of HIV infection in the state of Alabama (Alabama 
Department of Public Health, 2009). The UAB Internal Medicine Residency Program is a 3-year 
graduate medical training program accredited by the Accreditation Council for Graduate Medical 
Education and utilizes Baptist Medical Center–South in Montgomery as its primary teaching 
hospital. MAO is private, non-profit, community-based service organization that offers a variety 
of services, including medical treatment, mental health counseling, patient education, prevention 
education, and testing for individuals with or suspected of having HIV. There were no significant 
differences found between data collection sites on the main dependent variables. 
A priori power analyses indicated that 150 participants were sufficient to support the 
statistical analyses for the present study, assuming a large effect size, power of .80, and alpha 
level of .05. Data were collected on 200 patients with HIV/AIDS who presented during their 
routine medical examinations to monitor their HIV/AIDS status. Of these, 101 were male, 98 
were female, and 1 identified as transgendered. Their mean age was 43.22 (SD = 12.30), with 
ages ranging from 18 to 85. One hundred forty-eight (74.0%) were African-American, 42 
(21.0%) were Caucasian, 7 (3.5%) were Hispanic/Latino, and the remaining three were of other 
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ethnicities. Regarding sexual orientation, 148 (74.0%) identified as heterosexual, 43 (21.5%) 
identified as homosexual, and 9 (4.5%) identified as bisexual. The majority of participants were 
unmarried (62.0% single, 13.0% divorced, 5.5% widowed). Level of education varied 
considerably among the sample, with 32.5% having not completed high school, 39.5% having a 
high school diploma or GED, 18.0% completing some college, and 10.0% receiving a college 
degree and/or attending graduate school. Notably, 88 (44.0%) participants reported smoking 
cigarettes, the mean frequency of which was nearly a pack per day (19.86; SD = 6.24) and the 
mean duration of which was 22.65 years (SD = 11.08).  
Regarding HIV/AIDS characteristics of this sample, participants had been living with 
HIV for an average of 99.70 (SD = 69.29) months, with ranges from 2 to 282 months. 
Characterization of HIV/AIDS severity was made according to the World Health Organization’s 
(2007) classification for immunological staging based on most recent CD4 counts (number of 
CD4 cells per mm
3 
of blood). Seventy-four participants (37.0%) were classified as Not 
Significant (CD4 counts of 500 or greater), 40 (20.0%) were classified as Mild (CD4 of 350-
499), 58 (29.0%) were classified as Advanced (CD4 of 200-349), and 28 (14.0%) were classified 
as Severe (CD4 below 200; meeting criteria for AIDS). The mean CD4 count was 443.48 (SD = 
261.58). While CD4 counts are typically measured every 3 months in clinical settings, 
participants in this study had a mean of 43.52 (SD = 35.06) days since their last measurement. 
The overwhelming majority of the sample (93.5%) was prescribed ARVs at the time of data 
collection, 68% of whom were prescribed two or more ARVs. Participants were prescribed an 
average of 3.91 (SD = 1.92) total medications (ARV + non-ARV), and carried an average of 2.19 
(SD = 1.48) non-HIV comorbid diagnoses. Besides headache, other prominent medical diagnoses 
were Hypertension (38%), Major Depressive Disorder (20%), Hepatitis (14%), 
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Hypercholesterolemia (9%), Diabetes (8.5%), Anxiety Disorders (6%), Asthma (6.5%), and 
Bipolar Disorder (4%).  
Measures 
Demographic Questionnaire and Medical Records  
A demographic questionnaire obtained information pertaining to age, gender, marital 
status, race, sexual orientation, and level of education. Information obtained from each 
participant’s medical record was also documented on this form. This information included most 
recent CD-4 counts and viral loads, date of HIV diagnosis, and a list of all prescribed 
medications and non-HIV diagnoses. This form can be found in Appendix A. 
Structure Diagnostic Interview for Headache-Brief Version (SDIH) 
The SDIH (Penzien, Rains, & Holroyd, 1993) is a structured diagnostic interview 
designed to establish headache diagnoses according to the operational criteria of the International 
Headache Society (1988, 2004). In addition to facilitating the diagnosis of migraine and tension-
type headache, the SDIH also inquires about symptoms of cluster headache, posttraumatic 
headache, and medication overuse headache. We used a revised version of the original SDIH that 
accords with the most recent diagnostic criteria of the IHS (2004) and included questions about 
headache symptoms in relation to HIV infection. The formal diagnosis of a primary headache 
disorder was based on the semiology of the reported headache symptoms. The HIV infection 
itself and concurrent antiretroviral treatment were not considered to be a symptomatic cause of 
the headache, unless review of the patient’s medical records indicated the presence of 
opportunistic CNS infections (e.g., toxoplasmosis, meningitis, encephalitis) at the onset of or 
prior to the headaches, in which case headache secondary to infection was diagnosed. The script 
for this interview can be found in Appendix B. 
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Brief Headache Screen 
The Brief Headache Screen is a 6-item questionnaire designed to quickly screen for 
migraine, drug rebound headache, and other disabling headaches (Maizels & Burchette, 2003). 
The Brief Headache screen assesses frequency of disabling headaches, frequency of mild 
headaches, and frequency of medication use. Headache diagnoses based on the Brief Headache 
Screen have been well validated among medical patients presenting within multiple settings 
(Maizels & Burchette; Maizels & Houle, 2008). This form can be found in Appendix C. 
Headache Management Self-Efficacy Scale (HMSE) 
The HMSE was developed by French et al. (2000) and is used to measure self-efficacy of 
one’s ability to manage and prevent headaches. The HMSE is a 25-item self-report measure that 
uses a 7-point Likert type response format (1 = Strongly Disagree to 7 = Strongly Agree). The 
scale is broken down into 4 subscales: Positive Prevention, Negative Prevention, Positive Pain 
Management/Disability, and Negative Pain Management/Disability. Regarding the psychometric 
properties of the measure, French et al. (2000) reported that the scale showed strong internal 
consistency reliability (  = .90). The HMSE was also found to have high construct validity, 
correlating positively with the Headache Specific Locus of Control-Internal (HSLC-I; .40; 
Martin, Holroyd, & Penzien, 1990), the Interview of Coping Efforts-Headache Version-
Prevention (ICE-H:P; .54; Hill et al., 1999), and the Interview of Coping Efforts-Headache 
Version-Tolerance (ICE-H:T; .55; Hill et al., 1999). High scores on the HMSE are associated 
with lower levels of headache disability (r = -.24), and low scores on the HMSE are associated 
with increased headache severity (r = -.29; French et al., 2000). This measure can be found in 
Appendix D. 
Migraine Disability Assessment (MIDAS) 
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The MIDAS is a 5-item questionnaire that quantifies headache-related disability in terms 
of missed days of work or school, housework, and nonwork (family/leisure) activities over the 
past 3 months. Questions assess the number of missed days due to headache and the number of 
days in which headache reduced usual productivity by more than half. The total score reflects the 
summed total of days that were missed and in which productivity was limited due to headache. 
The MIDAS has consistently demonstrated satisfactory internal consistency, high test-retest 
reliability, and good concurrent validity (Lipton, Stewart, Sawyer, & Edmeads, 2001; Stewart, 
Lipton, Dowson, & Sawyer, 2001; Stewart et al., 1999). This form can be found in appendix E. 
Headache Impact Test (HIT-6) 
The HIT-6 was developed by Kosinski and colleagues (2003) as a brief questionnaire to 
measure the impact of headaches on one’s functioning and was used in conjunction with the 
MIDAS as criterion variables of headache-related disability. This 6-item measure asks the 
respondent to report the frequency with which headaches have limited one’s ability to function. 
Forced-choice responses are assigned a numerical value and summed to calculate the total score 
of headache impact (Range = 36-78). The HIT-6 has been found to be a reliable, valid, and 
internally consistent measure of headache impact in research on headache populations (Kawata 
et al., 2005; Kosinski et al., 2003). The HIT-6 is reprinted in appendix F.  
Anxiety Sensitivity Index – 3rd Edition (ASI-3) 
The ASI-3 was developed by Taylor et al. (2007) as an updated version of the original 
ASI (Peterson & Reiss, 1992) and the ASI-R (Taylor & Cox, 1998a, 1998b). The ASI scales 
were designed to quantify fear of anxiety sensitivity, or the belief that anxiety symptoms should 
be feared because they portend dangerous consequences. The ASI-3 is an eighteen-item self-
report and is rated on a 5-point Likert type scale (0 = Very little to 4 = Very much). The ASI-3 
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contains three subscales pertaining to anxiety sensitivity toward particular clusters of anxiety 
symptoms: Physical Concerns, Cognitive Concerns, and Social Concerns. Taylor and colleagues 
(2007) demonstrated that this most recent ASI has high internal consistency (Physical Concerns: 
 = 0.86, Cognitive Concerns:  = 0.91, and Social Concerns:  = 0.86) and high construct 
validity. This form can be found in Appendix G. 
Pain Anxiety Symptoms Scale (PASS)  
The PASS-20 was developed by McCracken and Dhingra (2002) as a shortened form of 
the original PASS (McCracken, Zayfert, & Gross, 1992). This 20-item Likert-scale instrument 
was designed to assess pain-related anxiety/fear of pain. The PASS is designed to assess four 
components of pain-related anxiety, including fear appraisal, cognitive anxiety, physiological 
anxiety, and escape/avoidance. Reliability and validity research has confirmed that the PASS-20 
is a strong substitute for the PASS when time and effort of participants is a concern, as all four 
subscales of the PASS-20 correlate with the original instrument above r = .90 (McCracken & 
Dhingra; Roelofs et al., 2004). Internal consistency of the PASS-20 is high (  = .91; McCracken 
& Dhingra), and the measure has demonstrated convergent validity with other measures of pain-
related constructs (Roelofs et al., 2004). The PASS-20 is reprinted in appendix H. 
Pain Catastrophizing Scale (PCS) 
The PCS was designed to measure exaggerated negative orientations towards pain 
(Sullivan, Bishop, & Pivik, 1995). This measure is a 13-item self-report measure that is rated on 
a 5-point Likert type scale (0 = Not at all to 4 = All). The PCS measures catastrophizing along 
three subscales: rumination, magnification, and helplessness. Internal consistency of the PCS is 
high (  = .87), and research has indicated that it has convergent validity (Sullivan et al., 1995). 
This form can be found in appendix I. 
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Depression Anxiety Stress Scale (DASS) 
The DASS was designed to assess symptoms of depression, anxiety, and stress within a 
single self-report measure (Lovibond & Lovibond, 1993). The DASS is a 42-item measure on 
which responses are rated on a 4-point Likert type scale (0 = Did not apply to me at all to 3 = 
Applied to me very much, or most of the time). For the Depression scale, scores from 0-9 are 
considered Normal, from 10-13 are considered Mild, from 14-20 are considered Moderate, from 
21-27 are considered severe, and scores of 28 and higher are considered extremely severe 
(Lovibond & Lovibond, 1993). For the Anxiety scale, scores from 0-7 are considered Normal, 
from 8-9 are considered Mild, from 10-14 are considered Moderate, from 15-19 are considered 
Severe, and scores of 20 and higher are considered Extremely Severe (Lovibond & Lovibond, 
1993). For the Stress scale, scores from 0-14 are considered Normal, from 15-18 are considered 
Mild, from 19-25 are considered Moderate, from 26-33 are considered severe, and scores of 34 
and higher are considered extremely severe (Lovibond & Lovibond, 1993). The various scales 
have demonstrated strong internal consistency: DASS total scale (  = .97), Depression subscale 
(  = .96), Anxiety subscale (  = .92), and Stress subscale (  = .95; Page, Hooke, & Morrison, 
2007). Lovibond and Lovibond’s component analysis of the DASS found the measure to have 
high construct validity and demonstrated that the scale items show adequate factor loadings. 
Further, strong correlations were found between the DASS Depression scale and the Beck 
Depression Inventory (r = 0.74, Beck & Steer, 1987) and between the DASS Anxiety scale and 
the Beck Anxiety Inventory (r = 0.81, Beck & Steer, 1990; Lovibond & Lovibond, 1995). The 
DASS is reprinted in appendix J. 
Procedure 
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All participants in this study were treated in accordance with the ethical guidelines and 
principles set forth by the American Psychological Association. Participants were recruited 
during their routine medical examinations at both sites over continuous weeks until complete 
data were obtained on 200 individuals. Thirty-six participants declined to participate. 
Participants provided written informed consent with the understanding that their participation 
was entirely optional and that they could withdraw at any time. After informed consent was 
obtained, one of the two primary researchers (a trained staff psychologist from the UAB Internal 
Medicine Program and a psychology graduate student from the University of Mississippi) 
administered the SDIH in a private setting in order to clarify headache-related symptoms, 
patterns, and intensity. Prior to administration, participants were screened for reading level using 
the Reading Scale of the WRAT-4 (Wilkinson & Robertson, 2006) due to documented low 
reading proficiencies in Central Alabama (Jackson et al., 1991; Bogie, 1995). Participants with a 
reading level below 7th grade were administered the informed consent documents and 
questionnaire measures orally (approximately 120 participants). All participants providing 
consent then completed a packet of the aforementioned questionnaires under the premise that the 
study’s results would help improve prognosis and treatment planning for individuals suffering 
from HIV. At the conclusion of their participation, all participants were offered a packet of self-
help information on dealing with HIV, depression, anxiety, and tips to help improve overall 
headache prognosis; those reporting significant psychopathology were provided referral 
information for local outpatient providers.  
Data Analysis 
Statistical analyses were conducted using PASW by SPSS version 17.0 for participants 
who had complete data for all variables of interest. Descriptive statistics and frequencies were 
 33 
 
used to report demographic statistics and headache symptoms and typologies among HIV 
patients. Correlational analyses were used to determine the relationship between CD4 counts, 
HIV duration, and headache severity/disability. An independent samples T-test was used to 
compare patients on the categorical variables of interest pertaining to headache characteristics 
(prevalence of migraine vs. TTH). Controlling for multiple comparisons, a MANOVA was 
conducted to analyze group differences between HIV patients with and without headache on 
levels of psychiatric comorbidity and the psychological variables of interest (pain 
catastrophizing, anxiety sensitivity, fear of pain). Significant findings on the MANOVA 
provided support to parse out results into separate ANOVAs. Determination of those variables 
predictive of headache-related disability and severity were made using a series of hierarchical 
linear regression analyses. In such analyses, demographic variables (age, gender) were entered 
simultaneously as the first block, CD4 counts were entered as the second block, depression and 
anxiety scores from the DASS were entered simultaneously as the third block, and the 
psychological variables of interest were entered iteratively and independently (as separate fourth 
blocks) to determine the proportion of headache-disability (MIDAS, HIT-6 scores) variance 
accounted for by each psychological factor.  
 
 
 
 
 
 
 
 34 
 
 
 
 
III. RESULTS 
Headache symptoms and diagnoses in HIV patients. (Study Goal 1) 
 
Headache prevalence. Of the 200 HIV/AIDS participants, 107 (53.5%) reported having 
headaches. Four participants’ headaches were attributable to secondary causes (2 with 
toxoplasmosis, 1 with meningitis, and 1 with posttraumatic headache) based on review of 
medical records and interview data, and these individuals with secondary headache typologies 
were thus not included in subsequent group comparisons. According to medical records, 39% of 
all participants carried a pre-existing headache diagnosis. Regarding demographic differences, 
the headache and non-headache patients did not differ on most demographic variables: mean age, 
years of education, or on distribution of gender or race. Importantly, the two groups did not 
differ either on duration of HIV or number of prescribed ARVs. Table 2 presents the data for 
demographic differences between the headache and non-headache participants. Most notably, the 
headache participants had significantly lower CD4 counts than did those without headache, but 
this difference was not attributable to differences in duration of HIV or prescribed ARVs.  
Headache diagnoses. Primary headache diagnoses were made based on ICDH-II (IHS, 
2004) criteria and obtained from responses to the SDIH. Two researchers reviewed each 
headache participant’s interview data and compared them to ICHD-II criteria to establish 
diagnoses independently: inter-rater agreement was 99.03% (102/103 primary diagnoses). The 
one discrepant diagnosis was resolved through discussion. Of the 103 with primary headache 
disorders, 88 (85.44%) met diagnostic criteria for migraine: 14 (13.59%) with episodic migraine 
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without aura, 8 (7.77%) with episodic migraine with aura, 11 (10.68%) with probable migraine, 
and 55 (53.40%) with chronic migraine. Fifteen patients (14.56% of those with headache) met 
criteria for TTH: 12 (11.65%) with episodic TTH, 1 (0.97%) with probable episodic TTH, 1 
(0.97%) with chronic TTH, and 1 (0.97%) with probable chronic TTH. Among participants with 
headache, 19 (18.45%) identified their headache as fitting the description of a dull, bilateral ache 
(IHS code 9.3, “Headache Attributed to HIV/AIDS”). Characteristics of reported headache 
symptoms of all participants, including those with headache attributed to HIV infection, are 
found in Table 3. The percentage of patients within each headache diagnosis (excluding the 1 
participant with chronic TTH and 2 participants with “probable” TTH diagnoses) reporting 
various headache symptomatology can be found in Table 4. 
 
Table 2  
 
Demographic Characteristics of the Headache vs. Non-Headache Samples    
                            
 
Variable 
 
Headache (n =103) 
 
Non-Headache (n=93) 
Mean CD4 count (SD) 326.70** (222.85)  585.51 (228.48) 
Mean age (SD)   43.28 (11.65)    43.16 (13.26) 
Gender (% female)   47.60    50.50 
Race (% African American)   74.80    73.10 
Marital Status (% single)   66.00    59.10 
Sexual orientation (% heterosexual)   66.00*    82.80 
Mean education (SD)   11.51(1.67)    11.71 (2.01) 
% smoker   77.70**      5.40 
Mean # ARVs (SD)     1.93 (0.95)      1.80 (0.96) 
Duration of HIV in months (SD) 103.07 (72.15)    95.84 (65.14) 
_________________________________________________________________ 
** p < .0001; *p < .05 
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Table 3  
 
Headache Characteristics of all Patients with Headache (n=103) 
 
 
Characteristic 
 
N (%) 
Pain Location 
    Frontal 65 (63.11) 
    Temporal  55 (53.40) 
    Supraorbital 22 (21.36) 
    Orbital   6 (5.83) 
    Occipital   5 (4.85) 
Pain Distribution 
    Unilateral 36 (34.95) 
    Bilateral 67 (65.05) 
Pain Features 
    Pulsating 53 (51.46) 
    Pressing/Tightening (Non-Pulsating) 50 (48.54) 
    Described as a Dull Bilateral Ache 19 (18.45) 
Pain Severity (0-10) 
    0-3 (mild)   1 (0.97) 
    4-5 (moderate) 10 (9.71) 
    6-10 (severe) 92 (89.32) 
Monthly Headache Frequency 
    <1 per month   1 (0.97) 
    1-14 per month 41 (39.81) 
    15-29 per month 39 (37.86) 
    30 per month 22 (21.36) 
Headaches Began 
    Before HIV Diagnosis 18 (17.48) 
    After HIV Diagnosis 85 (82.52) 
Aggravated by Exercise 81 (78.64) 
Phonophobia 85 (82.52) 
Photophobia 81 (78.64) 
Nausea 32 (31.07) 
Vomiting 14 (13.59) 
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Table 4 
 
Headache Characteristics by Diagnosis, Excluding Probable TTH (n=101) 
 
Symptom  EM without       
Aura 
n (%) 
EM with  
Aura  
n (%) 
Probable  
Migraine  
n (%) 
Chronic 
Migraine  
N (%) 
Episodic 
TTH  
n (%) 
Number 
diagnosed*  
14 (13.59)   8 (7.77) 11 (10.68) 55 (53.40) 12 (11.65) 
Pain Location 
    Frontal 10 (71.43)   3 (37.50)   7 (63.64) 39 (70.91)   4 (33.33) 
    Temporal    6 (42.86)   6 (75.00)   3 (27.27) 32 (58.18)   7 (58.33) 
    Supraorbital   1 (7.14)   1 (12.50)   3 (27.27) 15 (27.27)   1 (8.33) 
    Orbital   1 (7.14)   1 (12.50)   0 (0.00)   1 (1.82)   3 (25.00) 
    Occipital   0 (0.00)   1 (12.50)   0 (0.00)   2 (3.64)   2 (16.67) 
Pain Distribution 
    Unilateral   6 (42.86)   3 (37.50)   8 (72.73) 14 (25.45)   3 (25.00) 
    Bilateral   8 (57.14)   5 (62.50)   3 (27.27) 41 (74.55)   9 (75.00) 
Pain Features 
     Pulsating   6 (42.86)   7 (87.50)   3 (27.27) 33 (60.00)   2 (16.67) 
     Pressing/ 
     Tightening  
  8 (57.14)   1 (12.50)   8 (72.73) 22 (40.00) 10 (83.33) 
Described as a 
Dull Bilateral 
Ache 
  4 (28.57)   1 (12.50)   3 (27.27)   6 (10.91)   5 (41.67) 
Mild Pain   0 (0.00)   0 (0.00)   0 (0.00)   0 (0.00)   1 (8.33) 
Moderate Pain   1 (7.14)   1 (12.50)   0 (0.00)   0 (0.00)   6 (50.00) 
Severe Pain 13 (92.86)   7 (87.50) 11 (100.00) 55 (100.00)   5 (41.67) 
<1 per month   0 (0.00)   0 (0.00)   0  (0.00)   0 (0.00)   1 (8.33) 
1-14 per month 13 (92.86)   7 (87.50)   9  (81.82)   0 (0.00) 11 (91.67) 
15-29 per 
month 
  0 (0.00)   0 (0.00)   2  (18.18) 36 (65.45)   0 (0.00) 
30 per month   1 (7.14)^   1 (12.50)^   0  (0.00) 19 (34.55)   0 (0.00) 
Before HIV      
Diagnosis 
  2 (14.29)   1 (12.50)   3  (27.27)   3 (5.45)   9 (75.00) 
After HIV 
Diagnosis 
12 (85.71)   7 (87.50)   8  (72.73) 52 (94.55)   3 (25.00) 
Aggravated by 
Exercise 
13 (92.86)   8 (100.00)   6  (54.55) 52 (94.55)   2 (16.67) 
Phonophobia 14 (100.00)   8 (100.00)   6  (54.55) 54 (98.18)   2 (16.67) 
Photophobia 12 (85.71)   8 (100.00)   5  (45.45) 54 (98.18)   1 (8.33) 
Nausea   6 (42.86)   5 (62.50)   4  (36.36) 17 (30.91)   0 (0.00) 
Vomiting   2 (14.29)   4 (50.00)   2  (18.18)   6 (10.91)   0 (0.00) 
 *Percentages within this row refer to percentages of the entire headache sample. All other percentages are 
in reference to that particular diagnosis.  
^ These two participants were diagnosed with episodic migraine despite having daily headaches because 
they did not meet the 3-month duration criterion for chronic migraine specified in the ICHD-II.  
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The headache group had a mean pain severity of 7.83 (out of 10; SD = 1.60) and a mean 
of 16.84 (SD = 10.57) headaches per month, indicating severe pain and chronic frequency. 
Confirming the high severity and frequency of headache, scores on the MIDAS and HIT-6 were 
indicative of severe headache-related disability. The mean MIDAS score of those with headache 
was 132.13 (SD = 91.52) out of 270 maximum. The mean HIT-6 score was 68.58 (SD = 10.63) 
out of 78 maximum.  
Relationships between headache and HIV variables. Significant Pearson correlations 
were also found between CD4 counts and pain severity and headache frequency, indicating that 
progression of HIV is associated with increased head pain and frequency. Similarly, significant 
correlations were obtained between both CD4 counts and HIT-6 scores and CD4 counts and 
MIDAS scores (see Table 4), indicating that the progression of HIV is associated also with 
greater headache-related disability. Conversely, duration of HIV was not significantly related to 
headache disability, pain severity, and headache frequency. These correlations can be found in 
Table 5. 
Regarding the prevalence of migraine versus TTH diagnoses as a function of CD4 counts, 
an independent-samples t-test yielded significant differences (p < .0001) between headache 
diagnoses. Participants with a primary TTH diagnosis had a mean CD4 of 505.23 (SD = 370.29) 
compared to a mean of 293.35 (SD = 175.22) for those with a primary migraine diagnosis, 
indicating an association between the severity of HIV and the type of headache experienced 
(with migraine being associated with greater severity of HIV/lower CD4 counts). This difference 
was not a function of HIV duration, as the migraine and TTH groups did not differ on duration of 
HIV (109.87 months [SD = 71.90 vs. 94.54 months [SD = 82.49], respectively). 
 
 39 
 
Table 5 
Correlations for relationships between headache and HIV variables 
 
** p < .0001; *p < .002; NS = Not Significant 
Only 18 of 103 (17.5%) headache participants reported having headaches prior to being 
diagnosed with HIV. Of those participants, 11 (61.1%) reported no change in headache 
frequency, while three (16.7%) reported having headaches at least 10 more days per month after 
being diagnosed with HIV. Four (22.2%) participants’ ratings of headache pain intensity changed 
from mild to moderate in the months and years following their HIV diagnosis, while 14 (77.8%) 
reported no change. The majority of headache patients thus reported developing their headache 
symptoms subsequent to HIV infection, and though limited by a small sample size, the majority 
of those with preexisting headaches denied an increase in frequency after being diagnosed with 
HIV.  
Psychiatric symptoms and psychological variables between headache and non-headache 
HIV patients. (Study Goal 2) 
 CD4 HIV Duration 
 
MIDAS 
 
HIT-6 
 
Severity 
 
Frequency 
CD4   __    NS -.41** -.41** -.33* -.32* 
HIV Duration   NS     __   NS   NS   NS   NS 
MIDAS -.41**    NS   __  .80**  .58**  .79** 
HIT-6 -.41**    NS  .80**   __  .69**  .75** 
Severity -.33*    NS  .58**  .69**    __  .53** 
Frequency -.32*    NS  .79**  .75**  .53**   __ 
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Data for group (headache vs. non-headache) comparisons of psychological variables were 
first analyzed for multivariate assumptions and were found to be acceptably normal and linear. 
Prior to the multivariate analyses, the 103 primary headache and 93 non-headache HIV/AIDS 
participants were checked for multivariate outliers by group using Mahalanobis distance. Twelve 
outliers were found using a conservative p < .001 chi-squared cutoff (Mahalanobis distance < 
24.322) as suggested by Tabachnick and Fidell (2007). All multivariate analyses were run with 
and without outliers, resulting in minimal statistical discrepancy. Consequently, the outliers were 
retained in the results reported below. 
 The Wilks’ lambda multivariate criterion for overall group differences was significant, F 
(1, 195) = 62.68, p < .0001 (partial 
2
 = .67), indicating that the headache and non-headache 
participants differed on the combination of variables pertaining to psychiatric comorbidity and 
psychological functioning. Subsequent univariate ANOVAs confirmed that the headache group 
reported significantly higher scores on measures of depression (p < .0001; 
2
 = .56), anxiety (p < 
.0001; 
2
 = .56), stress (p < .0001; 
2
 = .54), pain catastrophizing (p < .0001; 
2
 = .66), anxiety 
sensitivity (p < .0001; 
2
 = .53), and fear of pain (p < .0001; 
2
 = .63) than did their non-
headache counterparts. Group means are presented in Table 6.  
The headache and non-headache groups’ scores on the DASS-42 were compared to 
assess differences in comorbid psychiatric symptoms of depression, anxiety, and stress. On the 
Depression scale, the headache group’s mean score of 27.17 was indicative of severe depressive 
symptomatology, while the mean score of the non-headache group was in the non-clinical range. 
On the Anxiety scale, the headache group’s mean score of 24.78 was indicative of extremely 
severe symptomatology, while the mean score of the non-headache group was in the non-clinical 
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range. On the Stress scale, the headache group’s mean score of 26.98 was indicative of severe 
symptomatology, while the mean score of the non-headache group was in the non-clinical range.  
Table 6 
Mean Group Scores for Psychiatric Comorbidity and Other Psychological Variables 
 
Variable 
 Headache 
(N = 103) 
M (SD) 
Non-Headache 
(N = 93) 
M (SD) 
 
F-value 
 
  p-value 
      
DASS Depression  27.17 (12.89) 4.03 (6.12)  248.95     < .0001 
DASS Anxiety     24.78 (11.98) 3.47 (5.75)  243.29     < .0001 
DASS Stress  26.98 (11.68) 5.70 (7.29)  228.47     < .0001 
Pain Catastrophizing  34.86 (14.59) 3.09 (6.32)  377.00     < .0001 
Anxiety Sensitivity  43.05 (19.55)   9.15 (10.90)  218.32     < .0001 
Fear of Pain  66.51 (28.62)   7.78 (13.08)  329.42     < .0001 
                 
Note: Higher scores reflect more severe psychological impairment. 
As with scores on the DASS, headache patients reported significantly higher levels of 
pain catastrophizing, fear of pain, and anxiety sensitivity than did HIV patients without 
headache. On the PCS, participants scoring above 24 are considered catastrophizers, while those 
scoring below 15 are non-catastrophizers (Sullivan et al., 1995). The headache group scored a 
mean of 34.86 (SD = 14.59), while the non-headache group had a mean of 3.09 (SD = 6.32). The 
PASS-20, a questionnaire used to measure fear of pain and pain anxiety, was originally normed 
on chronic pain patients with a mean total score of 38.62 (McCracken & Dhingra, 2002). The 
headache group’s mean score on the PASS was 66.51 (SD = 28.62), while the non-headache 
group’s mean was 7.78 (SD = 13.08). The ASI-3, a questionnaire used to measure anxiety 
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sensitivity, has mean score of 12.8 for a non-clinical population (Taylor et al., 2007). The 
headache group’s mean score on the ASI-3 was 43.05 (SD = 19.55), while the non-headache 
group scored a mean of 9.15 (SD = 10.90). As hypothesized, headache patients reported higher 
levels of physical concerns related to anxiety sensitivity than did their non-headache counterparts 
(15.14 [SD = 6.63] vs. 3.75 [SD = 4.50]; p < .0001; 
2
 = .50).  
        Prediction of headache-related disability by psychological variables. (Study Goal 3) 
Determination of those variables that predict headache-related disability and severity were made 
using a series of hierarchical linear regression analyses. In these analyses, demographic variables 
(i.e., age, gender) were entered simultaneously as the first block, CD4 counts were entered as the 
second block, depression and anxiety scores from the DASS were entered simultaneously as the 
third block, and the psychological variables of interest were entered iteratively and 
independently (as separate fourth blocks). This strategy was chosen to determine the proportion 
of headache-related disability variance (MIDAS, HIT-6 scores) accounted for by each 
psychological factor (i.e., headache self-efficacy, pain catastrophizing, fear of pain, anxiety 
sensitivity) above these other factors that have been shown to be associated with headache 
disability. The data presented below refer to incremental R
2 
changes and significant F-values and 
p-values of these incremental changes.  
After the entry of age and gender, CD4 counts accounted for a significant amount of 
variance (R
2
 = 16.43%, F(1, 99) = 19.83, p < .0001) on HIT-6 scores. Adding in scores from the 
DASS Depression and Anxiety subscales accounted for the largest amount of incremental 
variance (R
2
 = 47.54%, F(2, 97) = 66.95, p < .0001) on HIT-6 scores. When each was entered 
separately as the final block, the psychological factors of pain catastrophizing, fear of pain, and 
anxiety sensitivity remained significant: the PCS to yield R
2
 = 10.74%, F(1, 96) = 43.52, p < 
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.0001; the PASS to yield R
2
 = 15.00%, F(1, 96) = 74.08, p < .0001; and the ASI to yield R
2
 = 
9.72%, F(1, 96) = 37.77, p < .0001. 
Controlling for age and gender, CD4 counts accounted for a significant amount of 
variance (R
2
 = 16.32%, F(1, 99) = 20.42, p < .0001) on MIDAS scores. Adding in scores from 
the DASS Depression and Anxiety subscales again accounted for the largest amount of variance 
(R
2
 = 43.78%, F(2, 97) = 60.08, p < .0001) on MIDAS scores. The last blocks added in scores 
from the varying psychological factors to yield significant incremental variances: the PCS to 
yield R
2
 = 4.42%, F(1, 96) = 13.72, p < .0001; the PASS to yield R
2
 = 3.91%, F(1, 96) = 11.95, p 
< .002; and the ASI to yield R
2
 = 4.02%, F(1, 96) = 12.32, p < .002. Age and gender were weak 
predictors of headache-related disability, accounting for less than 5% of the variance in both the 
HIT-6 and the MIDAS.  
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IV. DISCUSSION 
The size and diversity of the HIV/AIDS population in this study allowed for considerable 
confidence in the striking results of the data analysis. With the help of staff from two HIV/AIDS 
clinics in Montgomery, AL, this study obtained detailed headache data on 200 HIV-infected 
individuals at varying stages of HIV/AIDS severity. Compared to the few existing studies on 
HIV-related headache, this study is unique for a number of reasons. Most notably, most of the 
few existing studies on headache in HIV/AIDS patients were conducted prior to the peak of 
HAART success, and thus the present study affords more accurate characterization of the current 
HIV-infected population. Second, the sample’s high percentage of ARV prescription and low 
percentage of diagnosed opportunistic infection provides a unique yet consistent sample in which 
secondary causes of HIV-related headache appear uncommon. Third, all participants were 
recruited during routine HIV medical appointments and were therefore presumed not to be under 
substantially differentiating levels of duress. Lastly, the current study was approached as a 
headache study on the HIV-infected population from a psychological perspective. With respect 
to previously published research available, to our knowledge no study has ever been conducted 
from such a comprehensive multidisciplinary approach.  
Although the few previous studies on HIV-related headache have focused primarily on 
secondary causes of HIV-related headache using neuroimaging technologies (Graham & 
Wippold, 2001; Goldstein, 1990; Singer et al., 1996), this study was aimed at identifying patterns 
of headache symptoms, primary headache diagnoses, and related psychological variables. The 
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results of this study are practical and could enhance the medical and mental health treatment of 
individuals with HIV/AIDS and comorbid headache disorders.  
Description of headache symptoms in HIV patients 
Headache prevalence. Previous headache studies on HIV populations have attempted to 
assess the prevalence of various headache diagnoses. Some studies have found stark contrasts not 
only in prevalence of headache, but in types of primary headache diagnoses among HIV-infected 
individuals. Mirsattari et al. (1998) and Singer et al. (1996) obtained headache prevalence rates 
of 38% and 43%, respectively, among HIV patients, while Evers et al. (2000) found that 60% 
suffered from headache. As previously noted, other studies have also indicated a range of 40% 
(Matthews et al., 2000) to 61% (Justice et al., 1999). In the present study, headache prevalence 
was 53.5%, confirming a broad generalization that approximately half of HIV-infected 
individuals suffer from headache.  
Of the 107 individuals with headache, three had previous diagnoses of opportunistic 
encephalic infections and one was classified as experiencing posttraumatic headaches 
(subsequent to a head injury). This evidence suggests that far fewer HIV-infected individuals 
experience the encephalic infections that have in the past been considered the cause of head pain. 
Though neuroimaging procedures were not employed in this study to rule out such infections, the 
overwhelmingly large absence of documented encephalic infections is likely attributable to the 
current era of HAART therapy, in that fewer HIV patients display neurological symptoms of 
opportunistic infections that would warrant neuroimaging. It is likely future studies in this area 
will yield similar results, indicating that while the presence of opportunistic infection in HIV-
infected individuals has decreased, headache prevalence has remained consistent.  
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Headache diagnoses. When considering specific headache diagnoses, results of previous 
studies are inconsistent. For instance, both Lipton et al. (1991) and Goldstein (1990) reported 
that headaches secondary to opportunistic infections comprised the majority of headache 
diagnoses among patients with HIV. Lipton et al. (1991) found only six patients with identifiable 
migraines and two with TTH out of 49 headache patients. Evers et al. (2000) found that, out of a 
sample size of 131 HIV-infected individuals, 21 (16%) suffered from migraine while 60 (45.8%) 
suffered from TTH, indicating a preponderance of TTH among primary headache diagnoses. 
Within these headaches, preexisting migraines improved while preexisting TTHs worsened over 
the course of HIV (Evers et al., 2000). Of the previous studies, our findings that migraine (and 
particularly chronic migraine) is the most common form of primary headache among individuals 
with HIV are consistent with the results obtained by Mirsattari et al. (1998), who likewise 
confirmed that the majority of HIV headache sufferers show a migrainous typology (75% 
migraine vs. 14% TTH).  
Notably, both Lipton et al. (1991) and Goldstein (1990) were published before the era of 
successful HAART, further suggesting that previously documented infectious causes of 
headache in this population have likely declined substantially. Further, methodological 
differences were noted between Evers et al. (2000) and the current study. Most notably, 93.5% of 
participants in the current study were prescribed ARVs, compared to only 65% in Evers et al. 
Additionally, the participants in the current study were all recruited during their routine 
examinations, while the participant pool in Evers et al. consisted of asymptomatic individuals 
presenting for routine examinations, individuals presenting with nonspecific complaints (e.g. 
dizziness), and individuals with AIDS-defining non-CNS opportunistic infections. The 
aforementioned methodological differences are of vast importance in terms of generalization to 
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the modern HIV population. Although during the HAART era, both Evers et al. and Mirsattari et 
al. (1998) were conducted too early to obtain samples in which almost all participants were 
prescribed ARVs. However, both their studies and the present study suggest that headache 
diagnoses in current HIV/AIDS patients are most commonly consistent with primary headache 
typologies (migrainous and TTH subforms), rather than attributable to the more sinister 
opportunistic infections that characterized the earlier studies.  
Regarding our attempt to characterize the “typical” primary headache pattern in HIV-
infected patients, our findings indicate an overwhelming majority of headaches classified as 
migraine (85.44%) over TTH (14.56%). Strikingly, 53.4% of those with headache were 
classified as having chronic migraine. The symptom presentation within these migraine 
diagnoses is somewhat atypical, however. For example, many chronic migraineurs reported pain 
characterized by a bilateral location (74.55%) and pressing/tightening quality (40%), features 
typically associated with TTH. Although headache patterns were predicted to be more consistent 
with the “Headache Attributed to HIV/AIDS” pattern of a dull, bilateral ache variable in onset, 
site, and intensity (IHS code 9.3), an alternate pattern emerged. Only 19 (18.45%) individuals 
diagnosed with a primary headache characterized their pain as a dull, bilateral ache. A primarily 
bilateral pain distribution was indeed evident, but the other most prevalent symptoms were 
severe pain that was aggravated by activity and co-occurring phonophobia and photophobia, all 
of which are prototypical features of migraine. Pain site and the presence of nausea and vomiting 
were variable throughout the sample, perhaps as a function of the wide distribution of HIV 
severity. 
CD4 and headaches. The results of the current study indicate striking differences 
between the headache and non-headache groups in terms of HIV/AIDS severity. From this 
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perspective, CD4 counts are clearly of central importance in predicting headache symptoms. As 
was evidenced anecdotally in this study, many individuals with HIV/AIDS know their most 
recent CD4 count reading and understand that their overall health is greatly affected by the rise 
and fall of that number. Consequently, Hypothesis 1a was, as expected, confirmed. The severity 
of HIV among the non-headache group was on average far less than that of the headache group 
(mean CD4 in non-significant vs. advanced range, respectively). This discrepancy indicates that 
the progression of HIV is strongly associated with the presence of headaches. Other headache-
related variables were also strongly associated with CD4 counts: headache frequency, headache 
severity, and headache-related disability were inversely related to CD4 count. That is, existing 
headaches become more frequent, more intense, and are more disabling as HIV progresses.  
HIV duration. In this sample, participants had been living with HIV for an average of 
99.70 months (8.31 years). Although originally hypothesized as an important factor in headache 
presentation, duration of HIV was not significantly associated with any headache-related variable 
in the present study. In conjunction with our finding that HIV duration was unrelated to CD4 
counts, these data suggest that the severity of HIV is a far more potent predictor of headache than 
is duration of HIV. The lack of a relationship with HIV duration is likely also a function of 
advances made in identification and distribution of ARVs – most notably the introduction of 
HAART. Given that this sample was involved in regular medical follow-ups specifically for 
HIV/AIDS, and that 93.5% of participants were prescribed ARVs, the present sample likely 
represents a profile of aggressive treatment that may not be reflective of individuals in 
underserved communities. Nevertheless, these findings speak indirectly to the efficacy of ARVs 
in transforming HIV/AIDS outcomes from a deadly to a more chronic illness.  
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The implications of this particular set of results highlight the importance of focusing on 
medical complaints (e.g. HIV, headaches) from a biopsychosocial perspective (Suls & Rothman, 
2004). Approaching medical illnesses from a multidisciplinary perspective can allow for the 
identification of important psychological factors such as stress, social support, and treatment 
compliance as a focus of treatment (Suls & Rothman, 2004). Within the context of HIV, 
emphasizing chronicity and adjustment over terminality may allow for improved treatment 
success in terms of comorbid physical and mental health outcomes.  
Effect of HIV on preexisting headaches. A large majority (82.5%) of the sample indicated 
that their headaches began after being diagnosed with HIV. Of those with preexisting headaches 
(n = 18), only three reported an increase in frequency and four reported an increase in pain 
intensity, indicating little effect of HIV on preexisting headaches. While Evers et al. (2000) 
found significant increases in frequency and pain intensity on preexisting TTHs following HIV 
infection, improvement was noted in preexisting migraines. On the other hand, Singer et al. 
(1996) excluded individuals with preexisting headaches from data analysis, while the majority of 
other previous studies focused upon HIV headaches either did not report the data or failed to 
address the issue. Due to such a small number of patients with preexisting headaches in the 
current study, our results in this particular domain should be considered cautiously.  
 Smoking and headache. A clear discrepancy between the headache and non-headache 
group was cigarette use, although this was an ancillary focus of the present study. In previous 
studies focused on headache prevalence and tobacco use, smokers were more likely to complain 
of headache than non-smokers (Aamodt, Stovner, Hagen, Brathen, & Zwart, 2006; Waldie, 
McGee, Reeder, & Poulton, 2008). In the present study, while only 5.4% of the non-headache 
group identified as smokers, 77.7% of the headache group endorsed cigarette use with an average 
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of almost one pack per day. While a clear cause-effect relationship cannot be obtained in this 
cross-sectional design, this finding adds to the practical treatment implications of this study for 
medical providers when discussing headaches with HIV-infected individuals. This finding also 
provides indirect evidence linking smoking to headache, but among a much more specific 
population than has been examined in previous studies on smoking and headache.  
Psychological variables between groups. The MANOVA and individual ANOVA results 
from this study all highlighted striking differences between the headache and non-headache 
groups on each measure of psychiatric symptoms and cognitive variables. As hypothesized, the 
headache group scored significantly higher on measures of depression, anxiety, stress, pain 
catastrophizing, anxiety sensitivity, and fear of pain than the non-headache group. As predicted, 
anxiety sensitivity pertaining to physical concerns was much greater in the headache group than 
non-headache group. 
These results may be interpreted to indicate that the individuals comprising the non-
headache group experienced psychological health comparable to that of the general population. 
Not only were they without headaches, but they were functioning at an optimal level of 
psychological well-being and coping well with the stress of HIV, likely because their HIV 
severity was typically within a non-significant range. Conversely, the headache group endorsed 
significant psychological distress. They were generally unhappy, anxious, and reacted poorly to 
their emotional dysfunction and HIV-related stressors, likely related to the fact that their HIV 
was at a much more advanced stage (i.e., they had higher CD4 counts). These findings can be 
used to help medical providers inform their patients that HIV is a manageable disease in which 
infected individuals can expect positive mental health outcomes if they are compliant and 
proactive with treatment options. 
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Headaches and depression, anxiety, and stress. Consistent with previous studies 
indicating high comorbidity between headaches and depression (Breslau, 1998; Hamelsky & 
Lipton, 2006; Lake et al., 2005), the results of this study found drastic differences between the 
headache and non-headache groups on endorsement of symptoms of depression. While the 
participants in the headache group averaged severe depressive symptomatology (83.5% reported 
at least mild symptoms of depression), the non-headache group indicated non-clinical levels of 
depression similar to those reported by non-depressed individuals in the general population.  
The headache versus non-headache group comparisons also replicated findings from 
previous studies showing high comorbidity between headaches and anxiety (Hamelsky & Lipton, 
2006; Saunders et al., 2008). The headache group in this study endorsed levels of anxiety that are 
considered in the Extremely Severe range (82.5% considered at least mildly anxious), compared 
to generally non-clinical levels of anxiety among the non-headache group. Given the polarizing 
results on symptoms of depression, the similar results for symptoms of anxiety are not surprising. 
The consistent combined presence of depression and anxiety in a headache population (Breslau, 
1998; Lake et al., 2005; Lanteri-Minet et al., 2005), particularly in those infected with HIV, 
suggests that these common psychiatric comorbidities should be given clinical attention in 
individuals with HIV, particularly those with advanced disease.  
As previously discussed, stress is an important factor in the onset and exacerbation of 
headaches (Holm et al., 1986; Levor et al., 1986; Houle & Nash, 2008). Consistent with findings 
on depression and anxiety, the headache group in this study reported significantly higher levels 
of stress than the non-headache group. Individuals with high comorbid levels of depression, 
anxiety, and stress, even in the general population, are in need of psychological treatment. When 
adding in problems related to headaches and HIV, the necessity of treatment increases 
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considerably. The presence of psychiatric illness, particularly depression (Gordillo, del Amo, 
Soriano, & Gonzalez-Lahoz, 1999; Kemppainen, 2001; Sledjeski, Delahanty, & Bogart, 2005) 
has been closely linked to poor HAART compliance (Department of Health and Human 
Services, 2009) and HIV disease progression (Evans et al., 1997; Judd et al., 2000; 
Ghebremichael et al., 2009), highlighting the importance of recognizing these issues among 
HIV-infected individuals. Such results are vastly important for the practical implications of the 
current study, and should be considered in the context of recommendations made by medical 
treatment providers. 
Headaches and catastrophizing. HIV/AIDS patients with headache reported significant 
difficulty in responding to and accurately estimating their ability to cope with that pain. This 
group displayed a catastrophizing profile consistent with that of other types of pain groups in 
previous studies (Burns et al., 2003; Tsui et al., 2007), adding to a limited body of research 
between headaches and catastrophizing. The high level of catastrophizing reported by this group 
is one likely explanation for the overall extreme scores indicated on the entire battery of self-
report measures. A resulting response style is characterized by exaggeration of pain, excessive 
helplessness, and pessimism about coping ability (Severeijns et al., 2001; Smitherman, 
Nicholson, Schafer, & Houle, in press; Sullivan et al., 2001).  
Headaches, anxiety sensitivity, and fear of pain. Regarding symptoms of anxiety 
sensitivity, the headache group endorsed considerably higher symptoms compared to the non-
headache group. Because anxiety sensitivity is associated with fearing ambiguous physical 
sensations (Asmundson, Norton, & Norton, 1999), it was predicted that such a pattern would be 
apparent. As previously discussed, anxiety sensitivity is important temporally in the fear of pain 
(Norton & Asmundson, 2004). Patients with headache in this study also reported higher fear of 
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pain than did those without headache, and at levels that exceeded those of a treatment-seeking 
group of chronic pain patients (McCracken & Dhingra, 2002). Patients from McCracken and 
Dhingra were primarily Caucasian women with back and limb pain of less than 3 years duration, 
and presumably without a diagnosis of HIV/AIDS. Although subjective pain severity cannot be 
compared directly between the two studies, duration of pain and reported severity of other 
medical/mental health problems likely influence fear of pain considerably.  
Results of the current study thus provide strong support for previous findings on the role 
of anxiety sensitivity, fear of pain, and psychological distress among individuals with chronic 
pain (Asmundson & Norton, 1995; Asmundson & Taylor, 1996; Asmundson, Norton, & Veloso, 
1999; Hursey & Jacks, 1992). Previous studies have established and confirmed the role of these 
factors primarily in samples of headache sufferers from the general population (Asmundson, 
Norton, & Veloso, 1999; Hursey & Jacks, 1992) and individuals with other chronic pain 
conditions (Asmundson & Norton, 1995; Asmundson & Taylor, 1996; Vlaeyen & Linton, 2000). 
The current study, while not focused primarily on the relationships among these variables, 
provides similar data confirming the role of these psychological factors in HIV patients who also 
have chronic headaches, a population that remains understudied from a psychological 
perspective.  
Patient Groupings. Clearly, two large but different groups of HIV patients participated in 
this study: one group that was relatively healthy, optimistic, accepting, and very informed about 
their illness and their own health status, and another group that was relatively unhealthy, 
pessimistic, less careful and knowledgeable about their health, and with a poorer treatment 
prognosis. The latter group tended to consistently report that they experienced both frequent and 
severe headaches as well as high levels of emotional distress, and catastrophized about their pain 
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and illness. The former group not only had better HIV lab data results, but they also denied 
occurrence of problematic headaches, reported much lower levels of emotional distress, and 
exhibited a greater knowledge of the HIV disease process and the importance of compliance with 
HAART, the latter of which was evident through the responses of patients during data collection 
and the clinical observations of the researchers. According to Gifford and Groessl (2002), the 
most successful self-managing HIV patients are knowledgeable about their medical profile, the 
HIV illness, and advances in treatment; motivated to change and sustain the necessary behaviors 
for treatment compliance; and engaged in behaviors to learn, practice, and adapt to new 
behavioral skills in order to set and achieve goals, rely on social supports, and communicate 
effectively with treatment providers. 
The stark division between the two HIV groups is consistent with findings from HIV 
treatment studies. Vervoort et al. (2009) studied predictors of HAART adherence based on the 
importance of accepting or not accepting the HIV diagnosis and necessity of treatment 
compliance. Patients who successfully adhered to HAART were those who engaged in a 
decision-making process to adhere to medication, who had thorough knowledge of medication 
and of the importance of adherence, and who exhibited positive behaviors and thoughts 
surrounding HAART, the HIV infection, and social support. Judd et al. (2000) confirmed the 
importance of adherence to HAART in a 2-year study that tracked changes in depression during 
treatment. In that study, mean CD4 counts rose while self-reported symptoms of depression 
decreased, as did the number of patients who endorsed concerns about their health. These data 
indicate that adherence to HAART not only improves HIV parameters, but is effective also at 
improving comorbid mood symptoms and health perceptions. Data from these studies confirm 
that adherence to HAART is multiply determined by a variety of patient factors and is associated 
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with better overall health and less psychological distress. Although the current study did not 
investigate HAART compliance, the patient subgroupings and response styles are consistent with 
the notion that those HIV patients whose illness is well-controlled with HAART have much 
better specific and global outcomes than do their sicker counterparts.  
Psychological variables as predictors of headache. The hierarchical regressions 
performed on this data set yielded important results. Age and gender were found to be largely 
unrelated to headache-related disability among this sample of individuals with HIV/AIDS. 
Instead, CD4 count and the psychological variables were important predictors of disability. 
Importantly, comorbid symptoms of depression and anxiety afforded significant prediction of 
disability beyond that accounted for by CD4 counts and the demographic variables. After 
accounting for depression and anxiety, each psychological variable (e.g., catastrophizing, anxiety 
sensitivity, fear of pain) independently resulted in significant prediction of headache-related 
disability, though the variances accounted for were far smaller than those explained by comorbid 
depression and anxiety.  
Given that cognitive psychological factors have never been addressed in research on 
HIV-infected individuals with headache, this set of results is particularly important. The findings 
of this study indicate that although the overriding influence of depression and anxiety are of 
primary importance, the influence of maladaptive cognitive processing remains an important 
predictor of headache-related disability. Although maladaptive cognitive processing is common 
in both depression and anxiety, as evidenced in Leung and Poon (2001), such symptoms in this 
study independently predicted headache-related disability specifically. These findings are 
consistent with those from previous studies, which have noted a strong relationship between 
catastrophizing and pain-related disability among patients with arthritis (Keefe et al., 2004) and 
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migraine patients without HIV (Holroyd et al., 2007). Practically, these results suggest that 
specific thought patterns and cognitive distortions should be addressed in treatment, perhaps in 
turn improving the psychological functioning and the impact of headache among individuals 
with HIV.  
Practical Implications  
One of the primary motives for this research was to provide meaningful, practical data to 
primary care physicians, infectious disease specialists, neurologists, HIV health care teams, and 
individuals diagnosed with HIV about headache patterns and related psychological functioning. 
The ultimate goal was to provide more detailed information about headache symptomatology in 
an attempt to answer questions about “typical” headaches in HIV/AIDS patients and the relative 
importance of various psychological factors that are often overlooked (Marchioni et al., 2006). 
The approach taken in this study was geared at displaying a transdisciplinary biopsychosocial 
model of collaboration between health professions (Suls & Rothman, 2004) in an attempt to 
discover more about HIV and its complications pertaining to headache.  
Among others, one practical benefit from the results of this study is the ability to present 
the data in the form of feedback to HIV-infected individuals. Accurate epidemiological data 
leads to improved illness management. When first diagnosed, an individual usually receives 
information about the importance of medication compliance. The results of this study highlight 
the importance of medication compliance due to strong correlations between CD4 counts, 
headache frequency, and psychological dysfunction, and in consideration of extant literature on 
HAART compliance and positive physical and mental health outcomes. By looking at these 
implications in such a broad manner, it seems practical for medical providers to attempt to 
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convince HIV-infected individuals that the most important factor is not the presence of HIV, but 
how the patient responds to the illness, its complications, and its management.  
The purpose of this applied research was to enhance understanding of headaches in the 
HIV/AIDS population in order to improve patient education and treatment strategies. Based on 
the results, the headache suffering HIV population would benefit from an increase in referrals for 
mental health treatment. In order to optimize such transdisciplinary treatment opportunities, 
mental health professionals would benefit from learning about the modern nature of HIV, its 
relationship with headaches, and the vicious cycle the two factors participate in with 
psychological problems. With a combination of rigid adherence to HAART through improved 
self-management and consistent psychotherapy (when indicated), the negative impact of HIV 
could potentially be greatly reduced through increases in CD4 counts, improved overall mental 
health, and education in ways to prevent and cope with headaches. 
Another important benefit of clarifying the prevalence of headache and its “typical” 
presentation in HIV patients is a potential reduction in medical costs associated with sometimes 
unnecessary invasive medical procedures (e.g., lumbar punctures, MRIs, CT scans) for which 
patients and the health care system incur high costs. These defensive practice techniques have 
traditionally been employed subsequent to complaints of head pain to rule out opportunistic 
infections such as meningitis, sinusitis, or neurosyphilis among individuals with HIV/AIDS 
(Many, 2009). Our data suggest that symptom patterns and causes of headache in HIV patients 
likely have changed over the years, coinciding with the development and proliferation of 
HAART that has reduced disease burden and improved the prognosis of living with HIV. With 
the added knowledge about typical patterns of headache in HIV-infected individuals, suggesting 
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that the majority of these headaches are consistent with migrainous subforms and not 
opportunistic infections, reductions in these costly medical procedures may result.  
Limitations and Directions for Future Research 
The most prominent limitation in this study was the length of the questionnaire packet 
administered in the context of high-traffic medical clinics, which in conjunction with the 
interview sometimes took more than an hour to complete. Screening with the WRAT-4 was 
initiated to increase validity among those of low reading levels, but added to the burden involved 
in data collection. Both in oral and written administration, some participants seemed to develop a 
bifurcated response style characterized by either a “defensive pride” in which they reported a 
healthy medical profile and denied comorbid problems, or in which they endorsed virtually all 
problems associated with HIV, headache, and emotional distress. These extremes in response 
styles embody the distinct HIV patient groups articulated by Vervoort et al. (2009) and are 
reflected in the highly significant group differences. Nonetheless, continued replication with 
similar samples is warranted given the extreme group differences observed. 
Another possible confounding variable was that the comparisons of data gathered from  
oral versus paper administration could not be analyzed. A significant portion of the sample in 
this study was not able to read above a 6
th
 grade level and were thus administered the informed 
consent documents and lengthy questionnaire measures orally, which further increased 
administration time. Participant reading level and readability forms and measures is an often-
ignored factor in psychological and health care research, yet is vital to address in the context of 
medical settings, particularly those in underserved, rural, and low income areas. Although group 
differences could not be analyzed on the basis of oral versus self-administered versions of data 
collection, previous studies have found no difference in mode of self-report administration 
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(Edwards, Holmes, & Carvajal, 1998; Hahn, Rao, Cella, & Choi, 2008; Kendrick & 
Hatzenbuehler, 2006; Weinberger, Oddone, Samsa, & Landsman, 1996). It appeared to the 
researchers that the length of the questionnaire was more explanatory in accounting for more the 
extreme response styles than was the method of administration. Regardless, when evaluating the 
results of this study, readers should consider these factors. 
Another limitation was the absence of neuroimaging procedures typically used to rule out 
secondary headache causes. As previously discussed, earlier studies in this area employed the 
use of neuroimaging in conjunction with self-reported headache symptoms and medical records 
to exclude secondary causes of headache. However, due to the scope and goals of the current 
study, such procedures were not employed. Our conclusions about secondary causes were 
informed by review of patient medical records, patient self-report of past or current encephalitic 
infections, and the characteristics of reported headache symptoms. Although our results suggest 
that most HIV patients with headache problems do not show evidence of secondary causes (or 
merit neuroimaging), future studies confirming these findings with neuroimaging techniques are 
clearly needed for more definitive confirmation. Future research could model the methodology 
of the current study while adding neuroimaging procedures to definitively rule out opportunistic 
encephalic infections in the modern HIV-infected individual. Although such a study would come 
at high cost, convincing results could lead to an overall reduction in future costs both to the HIV 
patient and society as a whole.  
Another minor limitation was that the population of this study consisted of a relatively 
small number of individuals with preexisting headaches. Given the nature of this study and its 
primary goals, this was not of great concern, but nonetheless limited conclusions pertaining to 
changes in headache patterns subsequent to HIV diagnosis. Because little research to date has 
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focused on this issue, future studies should look at HIV-infected individuals with headaches prior 
to diagnosis, preferably using longitudinal designs.  
In addition to the directions mentioned previously, future research in this area should 
include treatment studies that focus on aggressively treating HIV among patients with comorbid 
headache. Such studies would include both HAART and mental health treatment, with close 
monitoring of changes not only in HIV-related lab data but in headache characteristics and 
psychological functioning. In addition to extensive psycho-education regarding HIV, mental 
health treatment should focus on addressing comorbid psychopathology, improving coping skills, 
and teaching skills in behavioral migraine management (e.g., stress management, trigger 
identification, relaxation training). Other treatment studies could focus on the role of triptans and 
other migraine-specific medications in improving headache and quality of life among these 
individuals. The results of such studies could be used to develop protocols by which practitioners 
from multiple disciplines could efficiently teach newly identified HIV-infected individuals about 
medication compliance, managing comorbid headaches, and maintaining a healthy emotional 
state. 
In conclusion, research on headache among individuals with HIV has been sporadic and 
limited, which is striking given both its well-documented prevalence among this population and 
significant treatment advancements coinciding with the success of HAART. Our data suggest 
that slightly more than half of all patients with HIV have problematic headaches; that these 
headaches are highly frequent and typically of a migrainous presentation (with some atypical 
features); that their presence, frequency, severity, and resulting disability is strongly related to 
the severity (but not duration) of HIV/AIDS; and that these headaches are strongly associated 
with numerous psychological variables. 
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 86 
 
Demographic Questionnaire and Medical Records 
 
      
Participant ID: _______ 
 
Date: ____/____/______ Study/Clinic Site (circle one):   1. UAB     2. MAO 
 
Age: ___________ 
 
Most recent CD4 cell count: ___________        Date Taken: ____/____/______ 
 
Most recent viral load: _______________         Date Taken: ____/____/______ 
 
Date of HIV diagnosis: ____/____/______ 
 
 
 
Gender (Circle One):     1. Male       2. Female      3. Transgender   
 
Relationship Status (Circle One):  1. Single    2. Married    3. Divorced     
 
  4. Separated   5. Widowed   6. Unknown 
 
 
Race (Circle One):    1. African American        2. Asian        3. Hispanic/Latino              
 
             4. Native American/Pacific Islander    5. Caucasian         
   
             6. Other:______________________ 
 
Sexual Orientation (circle one):   1. Heterosexual   2. Homosexual   3. Bisexual     
 
 
Highest Level of Education (Circle One):    
 
   1
st
      2
nd
    3
rd
    4
th
    5
th
    6
th
    7
th
    8
th
    9
th
    10
th
    11
th
   
 
   12) H.S. Diploma/GED       13) Some College        
 
   14) College Diploma           15) Some Graduate School            
 
   16) Graduate Degree 
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Medications Taken by Patient: 
 
Medications                       Dosage                          Frequency_  
 
___________________________________________________ 
 
___________________________________________________ 
 
___________________________________________________ 
 
___________________________________________________ 
 
___________________________________________________ 
 
___________________________________________________ 
 
___________________________________________________ 
 
___________________________________________________ 
 
___________________________________________________ 
 
___________________________________________________ 
 
___________________________________________________ 
 
 
Medical Diagnoses: 
 
____________________________________________________ 
 
____________________________________________________ 
 
____________________________________________________ 
 
____________________________________________________ 
 
____________________________________________________ 
 
____________________________________________________ 
 
____________________________________________________ 
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APPENDIX B: STRUCTURE DIAGNOSTIC INTERVIEW FOR HEADACHE (SDIH)  
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1. Do you ever get headaches?  Yes    No 
 
Does the patient get more than one type of headache?    Yes    No 
 (Complete a separate brief interview form for each type of headache)     Headache   #1   #2   #3 
 
  2. Select all pain locations that apply to this type of headache: (You must check at least one) 
 
        frontal (A)      temporal (B)     occipital (C)     orbital (D)      supraorbital (E) 
 
  3. Select all that apply:    top of head (F)      base of neck (G)      nasal/facial (H) 
 
  4. What is the intensity of pain that the patient experiences with a typical headache?    
       ____ (Indicate rating from 0-10) 
    
 
 
  0        1            2           3            4            5          6           7             8              9            10 
 No           Slightly            Mildly             Painful               Very                      Extremely    
Pain           Painful            Painful                                       Painful                  Painful 
 
On average, how many headache-free days do you have each week?   _______ days 
 
 5. Which of the following symptoms are a “predominant feature” of this headache type 
(presume that the headache is untreated)? 
   
      Pain Location (Select only one):      Unilateral    Not Unilateral   
      Pain Features (Select only one):       Pulsating     Pressing/Tightening (non-pulsating)    
                                                                Other:____  
Structured Diagnostic Interview for Headache – Revised (Brief Version) 
 The following items are selected from the long version of the Structured Diagnostic Interview for 
Headache (SDIH). The SDIH is part of the Headache Evaluation and Diagnostic System (HEDS), which 
includes software for data entry and diagnostic decision-making. These materials are intended to 
facilitate diagnosis of selected recurrent, benign headaches according to both IHS (2004) and Ad Hoc 
Committee (1962) diagnostic criteria. Optimal use of this interview requires expertise with the diagnostic 
classifications and familiarity with the computer software and manual that accompany the interview. 
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*If pressing/tightening (non-pulsating) in quality:  
  Could this headache be best described as a dull ache that occurs on both sides of the head?  
   Yes   No 
 
  6. How often does the patient experience this type of headache pain?   ____ days per month  
 
  7. How long have these headaches been occurring at this rate?   ____ Months  Years 
 
Did these headaches begin before or after you were diagnosed with HIV?  
______ Before HIV diagnosis ______After HIV diagnosis 
 
*If these headaches began before you were diagnosed… 
  How often did they occur? __________ days with headache per month 
  How intense was the pain, on average?  ________ (1-10 scale used earlier)  
 
Since you were diagnosed with HIV, have you ever also been diagnosed with: 
 
 _________ Meningitis (Month/year of diagnosis: __________________) 
 _________ Encephalitis (Month/year of diagnosis: _________________) 
 _________ Other severe infection (Month/year of diagnosis: _______________) 
 
8. What is the total number of this type of headache ever experienced: 1  2-4  5-9  >10   
  ____ (Indicate total number experienced) 
 
  9. How long does this headache last if untreated or unsuccessfully treated? (If patient falls 
asleep and wakes up without headache, duration of attack is until waking up. Check unremitting 
ONLY if patient reports headaches always last at least 7 days in duration). (Indicate duration in 
minutes)  
 
 Unremitting OR  
       __ m h d Typical Average       __ m h d Typical Minimum          __ m h d Typical Maximum 
 
10. Has anything about this headache (except freq.) changed in the last 6 months?  Yes  No 
 If YES, explain:              
 
11. Is the patient’s typical headache pain aggravated by routine physical activities (i.e., walking, 
lifting)?  Yes   No 
       
12. Do any of the following symptoms occur with this headache?  
 
 Headache worsened by conversational noise levels (phonophobia) 
 Headache worsened by normal light (photophobia) 
 Nausea (Indicate intensity)      Mild     Moderate   Severe 
 Vomiting (Indicate intensity)   Mild     Moderate    Severe                   
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13. Does the patient ever experience symptoms before this headache pain begin?   Yes   No 
If YES, and if any of the reported symptoms provide evidence of focal cerebral cortical, and/or 
brainstem dysfunction, complete Appendix 1 
If NO, skip to #14 
 
14. Does this headache have severe unilateral orbital, supraorbital, and/or temporal pain, and/or 
does the interviewer suspect a cluster-type headache?   Yes    No  
 If YES, complete Appendix 2 
 If NO, skip to #15 
 
15. Does the patient use any medications to relieve headache pain?    Yes    No 
  If YES, complete #15a, #15b, #15c 
  If NO, skip to #16 
 
 15a. How long has the patient been using the medication(s) to relieve headache pain?   
       ____ d w m y (Indicate duration in days, weeks, months, or years) 
 
15b. What is the frequency of medication use?_ days per week__ days per month__times per day 
 
15c. Did this headache develop or markedly worsen during medication overuse?   Yes    No 
               If YES, complete Appendix 3 
               If NO, skip to #16  
 
16. Is this headache related to any head injury or trauma?    Yes    No 
 If YES, complete Appendix 4 
 If NO, skip to #17 
 
17. Is this headache suspected to be attributed to a physical or other neurological disorder?  
  Yes    No 
 
*Complete the respective Appendices below if the patient “YES” to #13 (Aura Symptoms—Appendix 1), #14 
(Cluster headache Symptoms—Appendix 2), #15-C (Medication Overuse Symptoms—Appendix 3), or #16 
(Posttraumatic Headache Symptoms—Appendix 4) 
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1.          1. How many aura attacks has the patient experienced? ____  
                              
2.          2. What best describes the aura symptoms? (Select all that apply) 
        At least one aura symptom develops gradually over more than 4 minutes, 
AND/OR 2 or more symptoms occur in succession over 4 minutes 
                       Each aura symptom lasts longer than 4 minutes but less than 60 minutes 
        Headache begins during aura OR follows aura with a headache-free interval of 
less than 60 minutes 
                  
 3. Indicate which of the following aura symptoms are present during this type of 
headache: (Select all that apply) 
             X SYMPTOM  X SYMPTOM 
         P         Loss of sight (scotoma)               Uncoordinated movements (ataxia) 
         
            Scintillation (rapidly oscillating 
visual pattern) 
                                           Dizziness (vertigo) 
                     Blurred vision 
                              
  
             Ringing in ears (tinnitus) 
           
            Fortification spectra (zig-zag 
lines) 
                                Decreased hearing acuity 
                     Double vision 
                  
  
             Decreased level of consciousness 
         
 Tingling or numbness 
(paresthesias) 
             Aphasia or unclassifiable speech 
                  Weakness (paresis) 
               
 
Poorly articulated speech 
(dysarthria) 
                APPENDIX 1 Migraine Aura Symptoms 
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          APPENDIX 2 Cluster Headache Symptoms 
                   
                1. Have the headaches occurred in cluster periods?    Yes    No 
                              If YES, complete #1a 
                              If NO, skip to #2 
 
                 1a. What is the total number of cluster periods experienced?  ____  
  
     1b. What is the duration of cluster periods?____ d w m y  
      (Indicate duration in days, weeks,  months, or years)                                                                                                                                          
 
     2. Are the headaches separated by remission periods?    Yes    No 
                              If YES, complete #2a 
                              If NO, skip to #3 
 
           2a. What is the duration of remission periods?____ d w m y  
            (Indicate duration in days, weeks,  months, or years) 
 
               3. Indicate which of the following symptoms are present, as well as side affected, 
during this type of headache: (Select all that apply) 
  X SYMPTOM            SIDE X        X SYMPTOM 
                       
SIDE 
                                                        
                        
Red eyes (conjunctival
injection) 
           R     L            
Forehead and facial 
sweating 
           R     L 
       
Tearing of the eyes 
(lacrimation) 
           R     L            
Pupillary constriction 
(miosis) 
           R     L 
           Nasal congestion            R     L            
Drooping eyelids 
(ptosis) 
           R     L 
          Runny nose (rhinorrhoea)             R     L               
Eyelid swelling 
(oedema) 
            R     L 
                     Restlessness or agitation                                         Other:  
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         APPENDIX 3 Medication-Overuse Headache Symptoms 
            1. Has the patient withdrawn from the overused medication?    Yes    No 
                            If YES, complete #1a and #1b 
                              If NO, skip to #2 
 
              1a. Did headache resolve or revert to its previous pattern within 2 months after 
discontinuation of overused medication?    Yes    No 
         
1b. Has medication overuse ceased within the last 2 months, but headache has not 
resolved or reverted back to its previous pattern?    Yes   No 
 
             2. Has intake of ergotamine, triptan, opioid OR combination of ergotamine, triptan, 
opioid, or analgesic occurred on 2 or more days per week, for 10 or more days per 
month, for greater than 3 months (Must not have combination overuse of any single 
class alone)?    Yes    No 
 If YES, indicate drug(s):     ergotamine    triptan    opioid    analgesic  ___  
                         
 3. Has the patient’s intake of analgesic occurred on 2 or more days per week, for 15 or 
more days per month, for greater than 3 months?    Yes    No     
          If YES, indicate drug: ___________  
            
             4. Has the patient’s intake of combination analgesics occurred on 2 or more days per 
week, for 10 or more days per month, for greater than 3 months?     Yes    No   
If YES, indicate drugs: ________________________ 
              
5. Has the patient’s intake of medication other than ergotamine, triptan, analgesic, or 
opioid occurred  on a regular basis for greater than 3 months?   Yes    No    
             If YES, indicate drug: _____________________ 
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         APPENDIX 4 Post-Traumatic Headache Symptoms 
  1. Was there a loss of consciousness associated with head trauma?    Yes    No   
 If YES, complete #1a 
 If NO, skip to #2 
 
  1a. What was the duration of unconsciousness?____ m h d (Indicate duration in      
minutes, hours, or days) 
 
   2. Is head injury attributed to whiplash?    Yes    No 
      If YES, skip #5 through #8  
       If  NO, complete #3 through #8 
 
   3.Did headache develop within 7 days after head trauma (or after regaining 
consciousness)?     Yes    No 
 
   4. How long has the headache continued? (Select most representative category) 
  Resolves within 3 months after head trauma 
  Persists for greater than 3 months after head trauma 
  Persists but 3 months have not passed since head trauma 
 
   5. Did coma develop?    Yes    No  
      If YES, indicate severity on Glasgow Coma Scale: 
        GCS <13 [moderate/severe]    GCS >13 [mild]              
  
   6. Did post-traumatic amnesia develop and continue for longer than 48 hours?                  
 Yes    No 
 
   7. Did symptoms/signs develop diagnostic of a concussion?     Yes    No 
 
   8. Were abnormal neuroimaging results attained suggestive of a traumatic brain 
lesion?  Yes   No 
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Appendix C: BRIEF HEADACHE SCREEN 
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Brief Headache Screen 
 
Check the best answer for each question below. 
 
1. How often do you get severe headaches (difficult or unable to continue normal function)? 
            _____ Daily or near daily 
            _____ 3-4 days per week 
 _____ Between 2 days per week and 2 days per month 
 _____ Once a month or less 
 _____ Almost never 
 
2. How often do you get mild or less severe headaches?  
            _____ Daily or near daily 
            _____ 3-4 days per week 
 _____ Between 2 days per week and 2 days per month 
 _____ Once a month or less 
 _____ Almost never 
 
3. How often do you take pain relievers, or any medication to relieve headache symptoms?  
            _____ Daily or near daily 
            _____ 3-4 days per week 
 _____ Between 2 days per week and 2 days per month 
 _____ Once a month or less 
 _____ Almost never 
 
4. How often do you miss some work or leisure time because of headache?  
            _____ Daily or near daily 
            _____ 3-4 days per week 
 _____ Between 2 days per week and 2 days per month 
 _____ Once a month or less 
 _____ Almost never 
 
5. Are you satisfied with the current medication you use to relieve your headaches? 
            _____ Yes 
            _____ No 
 
6. Are you taking daily prescription medication to prevent headaches? 
            _____ Yes 
            _____ No 
 
7. If no, do your headaches trouble you enough to take daily preventive medication? 
            _____ Yes 
            _____ No 
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APPENDIX D: HEADACHE MANAGEMENT SELF-EFFICACY SCALE 
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HMSE 
Instructions: You will find below a number of statements related to headaches. Please read each 
statement carefully and indicate how much you agree or disagree with the statement by circling a 
number next to it. Use the following scale as a guide: 
 
Strongly 
Disagree 
1 
Moderately 
Disagree 
2 
Slightly 
Disagree 
3 
Neither 
Agree or 
Disagree 
4 
Slightly 
Agree 
5 
Moderately 
Agree 
6 
Strongly 
Agree 
7 
 
1. I can keep even a bad headache from disrupting my 
day by changing the way I respond to the pain. 
1 2   3   4   5    6   7 
2. When I’m in some situations, nothing I do will prevent 
headaches.* 
         1    2   3   4    5    6   7 
3. I can reduce the intensity of a headache by relaxing. 1 2   3   4    5    6   7 
4. There are things I can do to reduce headache pain. 1 2   3   4    5    6   7 
5. I can prevent headaches by recognizing headache 
triggers. 
1  2   3   4   5    6   7 
6. Once I have a headache there is nothing I can do to 
control it.* 
1  2    3   4   5   6   7 
7. When I’m tense, I can prevent headaches by 
controlling the tension. 
1  2    3    4   5   6   7 
8. Nothing I do reduces the pain of a headache.* 1  2    3    4   5   6   7 
9. If I do certain things every day, I can reduce the 
number of headaches I will have. 
1  2    3    4   5   6   7 
10. If I can catch a headache before it begins I often can 
stop it. 
          1     2    3    4   5   6   7 
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1. N         11. Nothing I do will keep a mild headache from 
turning into a bad headache.* 
          1    2    3    4    5    6    7 
12. I can prevent headaches by changing how I respond 
to stress. 
1 2    3    4    5    6    7 
13. I can do things to control how much my headaches 
interfere with my life. 
1 2    3     4   5    6    7 
14. I cannot control the tension that causes my 
headaches.* 
1 2    3     4   5    6    7 
15. I can do things that will control how long a 
headache lasts. 
1 2    3     4   5    6    7 
16. Nothing I do will keep a bad headache from 
disrupting my day.* 
 1    2    3    4   5    6    7 
17. When I’m not under a lot of stress I can prevent 
many headaches. 
 1    2    3    4   5    6    7 
18. When I sense a headache is coming, there is 
nothing I can do to stop it. * 
1 2    3    4   5    6    7 
19. I can keep a mild headache from disrupting my day 
by changing the way I respond to the pain. 
 1    2     3    4   5   6    7 
20. If I am under a lot of stress there is nothing I can do 
to prevent headaches.* 
 1    2     3    4   5   6    7 
21. I can do things that make a headache seem not so 
bad. 
1    2     3    4   5   6    7 
22. There are things I can do to prevent headaches.  1    2     3     4   5   6   7 
23. If I am upset there is nothing I can do to control the 
pain of a headache.*  
1    2     3     4   5   6   7 
24. I can control the intensity of headache pain.  1    2     3     4   5   6   7 
25. I can do things to cope with my headaches.            1    2     3     4   5   6    7 
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APPENDIX E: MIGRAINE DISABILITY ASSESSMENT (MIDAS) 
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MIDAS 
 
Write in your answer for each question below.  
 
             1. On how many days in the last 3 months did you miss work or school because of 
your          headaches?    
 
_____   _____ days 
  2. How many days in the last 3 months was your productivity at work or school    
reduced by half or more because of your headaches?  
(Do not include days you counted in question 1 where you missed work or 
school.)  
 
_____ days 
3. On how many days in the last 3 months did you not do household work because    
of your headaches?  
 
______ days 
  4. How many days in the last 3 months was your productivity in household work 
reduced by half or more because of your headaches?  
(do not include days you counted in question 3 where you did not do household 
work.)  
 
______ days 
5. On how many days in the last 3 months did you miss family, social or leisure 
activities because of your headaches?  
 
______ days 
 6. On how many days in the last 3 months did you have any 
headache?  
   (If a headache lasted more than 1 day, count each day.)  
 
______ days 
 7. On a scale of 0 - 10, on average how painful were these 
headaches?  
  (where 0 = no pain at all and 10 = pain as bad as it can be.)  
 
______  
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APPENDIX F: HEADACHE IMPACT TEST – 6 (HIT-6) 
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HIT-6 
 
 
This questionnaire was designed to help you describe and communicate the way you feel and 
what you cannot do because of headaches. 
 
To complete, please circle one answer for each question. 
 
 
1) When you have headaches, how often is the pain severe? 
 
    Never     Rarely     Sometimes     Very     Often     Always 
 
2) How often do headaches limit your ability to do usual daily activities including 
household work, work, school, or social activities? 
 
    Never     Rarely     Sometimes     Very     Often     Always 
 
3) When you have a headache, how often do you wish you could lie down? 
 
    Never     Rarely     Sometimes     Very     Often     Always 
 
4) In the past 4 weeks, how often have you felt too tired to do work or daily activities 
because of your headaches? 
 
    Never     Rarely     Sometimes     Very     Often     Always 
 
5) In the past 4 weeks, how often have you felt fed up or irritated because of your 
headaches? 
 
    Never     Rarely     Sometimes     Very     Often     Always 
 
6) In the past 4 weeks, how often did headaches limit your ability to concentrate on work or 
daily activities? 
 
    Never     Rarely     Sometimes     Very     Often     Always 
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APPENDIX G: ANXIETY SENSITIVITY INDEX – THIRD EDITION (ASI-3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 106 
 
 
ASI-3 
  
Please circle the number that best corresponds to how much you agree with each item. If any 
items concern something that you have never experienced (e.g., fainting in public), then answer 
on the basis of how you think you might feel if you had such an experience. Otherwise, answer 
all items on the basis of your own experience. Be careful to circle only one number for each item 
and please answer all items. 
 
 Very 
little 
A 
little 
Some Much Very 
much 
1. It is important for me not to appear nervous.  0 1 2 3 4 
2. When I cannot keep my mind on a task, I 
worry that I might be going crazy. 
0 1 2 3 4 
 
3. It scares me when my heart beats rapidly.  0 1 2 3 4 
4. When my stomach is upset, I worry that I 
might be seriously ill. 
0 1 2 3 4 
5. It scares me when I am unable to keep my 
mind on a task. 
0 1 2 3 4 
6. When I tremble in the presence of others,  
 I fear what people might think of me.  
0 1 2 3 4 
 
7. When my chest feels tight, I get scared that I 
won’t be able to breathe properly.  
0 1 2 3 4 
 
8. When I feel pain in my chest, I worry that 
I’m going to have a heart attack.  
0 1 2 3 4 
 
9. I worry that other people will notice my 
anxiety.  
0 1 2 3 4 
10. When I feel “spacey” or spaced out I worry 
that I may be mentally ill.  
0 1 2 3 4 
11. It scares me when I blush in front of people.  0 1 2 3 4 
12. When I notice my heart skipping a beat, I 
worry that there is something seriously 
wrong with me.  
0 1 2 3 4 
 
13. When I begin to sweat in a social situation,  
 I fear people will think negatively of me.  
0 1 2 3 4 
 
14. When my thoughts seem to speed up, I 
worry that I might be going crazy.  
0 1 2 3 4 
 
15. When my throat feels tight, I worry that I 
could choke to death.  
0 1 2 3 4 
16. When I have trouble thinking clearly, I 
worry that there is something wrong with 
me.  
0 1 2 3 4 
 
17. I think it would be horrible for me to faint in 
public.  
0 1 2 3 4 
18. When my mind goes blank, I worry there is 
something terribly wrong with me.  
0 1 2 3 4 
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APPENDIX H: PAIN ANXIETY SYMPTOMS SCALE (PASS-20) 
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PASS-20 
Individuals who experience pain develop different ways to respond to that pain. We 
would like to know what you do and what you think about when in pain. Please use      
the rating scale below to indicate how often you engage in each of the following thoughts 
or activities. Circle any number from   0 (NEVER) to 5 (ALWAYS) for each item.  
 
1. I think that if my pain gets too severe, it will never decrease……. . .0  1  2  3  4  5 
 
2. When I feel pain I am afraid that something terrible will happen……0  1  2  3  4  5 
 
3. I go immediately to bed when I feel severe pain …..…..…………….0  1  2  3  4  5 
 
         4. I begin trembling when engaged in activity that increases pain………0  1  2  3  4  5 
 
5. I can’t think straight when I am in pain ……. ……………………… 0  1  2  3  4  5 
 
6. I will stop any activity as soon as I sense pain coming on …….……0  1  2  3  4  5 
 
         7. Pain seems to cause my heart to pound or race …….……………….. 0  1  2  3  4  5 
 
8. As soon as pain comes on I take medication to reduce it ……. …….0   1  2  3  4  5 
 
9. When I feel pain I think that I may be seriously ill ……. ………… 0   1  2  3  4  5 
   
         10. During painful episodes it is difficult for me to think of  
 anything else besides the pain…………………………………………0   1  2  3  4  5 
 
         11. I avoid important activities when I hurt …………………………... 0  1  2  3  4  5 
 
         12. When I sense pain I feel dizzy or faint ……………………………..0  1  2  3  4  5 
 
         13. Pain sensations are terrifying ………………………………………0  1  2  3  4  5 
 
         14. When I hurt I think about the pain constantly ……………………. 0  1  2  3  4  5 
 
         15. Pain makes me nauseous (feel sick)………………………………. 0  1  2  3  4  5 
   
         16. When pain comes on strong I think I might become  
   paralyzed or more disabled ………………………………………. 0  1  2  3  4  5 
 
         17. I find it hard to concentrate when I hurt ………………………….. 0  1  2  3  4  5 
 
         18. I find it difficult to calm my body down after periods of pain …….0  1  2  3  4  5 
                     NEVER     ALWAYS 
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19. I worry when I am in pain …………………………………………0  1  2  3  4  5 
 
20. I try to avoid activities that cause pain ……………………………0  1  2  3  4  5 
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Pain Catastrophizing Scale  
 
Instructions:  
We are interested in the types of thoughts and feelings that you have when you are in pain. Listed 
below are thirteen statements describing different thoughts and feelings that may be associated 
with pain. Using the following scale, please indicate the degree to which you have these thoughts 
and feelings when you are experiencing pain.  
 
RATING       0       1       2       3       4  
MEANING  Not at all  To a slight 
degree  
   To a 
moderate 
degree  
To a great 
degree  
All the time  
 
 
                When I’m in pain...                                                              RATING   
 
1. I worry all the time about whether the pain will end.          _________       
2. I feel I can’t go on.              _________ 
3. It’s terrible and I think it’s never going to get any better.         _________  
4. It’s awful and I feel that it overwhelms me.           _________ 
5. I feel I can’t stand it anymore.                        _________ 
6. I become afraid that the pain will get worse.           _________  
7. I keep thinking of other painful events.                       _________ 
8. I anxiously want the pain to go away.            _________ 
9. I can’t seem to keep it out of my mind.                       _________ 
10. I keep thinking about how much it hurts.            _________  
11. I keep thinking about how badly I want the pain to stop.                     _________  
12. There’s nothing I can do to reduce the intensity of the pain.         _________ 
13. I wonder whether something serious may happen.                              _________ 
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APPENDIX J: DEPRESSION ANXIETY STRESS SCALE (DASS) 
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DASS 42 
Please read each statement and circle a number 0, 1, 2, or 3, which indicates how much the 
statement applied to you over the past week. 
The rating scale is as follows: 
0 Did not apply to me at all 
1 Applied to me to some degree, or some of the time. 
2 Applied to me a considerable degree, or a good part of the time. 
3 Applied to me very much, or most of the time. 
1. I found myself getting upset by quite trivial things 0 1 2 3 
2. I was aware of dryness of my mouth 0 1 2 3 
3. I couldn't seem to experience any positive feeling at all 0 1 2 3 
4. I experienced breathing difficulty (e.g., excessively rapid 
breathing, breathlessness in the absence of physical exertion) 
0 1 2 3 
5. I just couldn't seem to get going 0 1 2 3 
6. I tended to over-react to situations 0 1 2 3 
7. I had a feeling of shakiness (e.g., legs going to give way) 0 1 2 3 
8. I found it difficult to relax 0 1 2 3 
9. I found myself in situations that made me so anxious I was 
most relieved when they ended 
0 1 2 3 
10. I felt that I had nothing to look forward to 0 1 2 3 
11. I found myself getting upset rather easily 0 1 2 3 
12. I felt that I was using a lot of nervous energy 0 1 2 3 
13. I felt sad and depressed 0 1 2 3 
14. I found myself getting impatient when I was delayed in any 
way (e.g., lifts, traffic lights, being kept waiting) 
0 1 2 3 
15. I had a feeling of faintness 0 1 2 3 
16. I felt that I had lost interest in just about everything 0 1 2 3 
17. I felt I wasn't worth much as a person 0 1 2 3 
18. I felt that I was rather touchy 0 1 2 3 
19. I perspired noticeably (e.g., hands sweaty) in the absence of 
high temperatures or physical exertion 
0 1 2 3 
20. I felt scared without any good reason 0 1 2 3 
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21. I felt that life wasn't worthwhile 0 1 2 3 
22. I found it hard to wind down 0 1 2 3 
23. I had difficulty in swallowing 0 1 2 3 
24. I couldn't seem to get any enjoyment out of the things I did 0 1 2 3 
25. I was aware of the action of my heart in the absence of 
physical exertion (e.g., sense of heart rate increase, heart 
missing a beat) 
0 1 2 3 
26. I felt down-hearted and blue 0 1 2 3 
27. I found that I was very irritable 0 1 2 3 
28. I felt I was close to panic 0 1 2 3 
29. I found it hard to calm down after something upset me 0 1 2 3 
30. I feared that I would be "thrown" by some trivial but 
unfamiliar task 
0 1 2 3 
31. I was unable to become enthusiastic about anything 0 1 2 3 
32. I found it difficult to tolerate interruptions to what I was 
doing 
0 1 2 3 
33. I was in a state of nervous tension 0 1 2 3 
34. I felt I was pretty worthless 0 1 2 3 
34. I was intolerant of anything that kept me from getting on 
with what I was doing 
0 1 2 3 
36. I felt terrified 0 1 2 3 
37. I could see nothing in the future to be hopeful about 0 1 2 3 
38. I felt that life was meaningless 0 1 2 3 
39. I found myself getting agitated 0 1 2 3 
40. I was worried about situations in which I might panic and 
make a fool of myself 
0 1 2 3 
41. I experienced trembling (e.g., in the hands) 0 1 2 3 
42. I found it difficult to work up the initiative to do things 0 1 2 3 
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Consent to Participate in an Experimental Study 
Title: Psychological Factors in HIV-Related Headaches 
 
             Investigator 
             Kale E. Kirkland, M.A. 
             Department of Psychology 
             302B Peabody Hall 
             The University of Mississippi 
             (334) 391-1719 
            Faculty Advisor 
            Todd A. Smitherman, Ph.D. 
            Department of Psychology 
  302D Peabody Hall 
            The University of Mississippi 
            (662) 915-1825 
 
Description 
Many individuals with HIV experience headaches. We are asking you to participate in a research 
study that will evaluate the relationship between your headaches and psychological factors. This 
study requires you to undergo a brief interview about your headaches and to complete a packet of 
questionnaires related to depression, anxiety, stress, and pain. The administration of the 
instruments will take approximately 30-45 minutes to be completed. We will also be gathering 
some data from your medical records, including the date of your HIV diagnosis and your most 
recent CD4 and viral load counts.  
 
Risks and Benefits 
Your participation in this study is entirely voluntary. Interviews will be conducted in a 
private setting to assure your privacy. You may feel uncomfortable answering questions about 
symptoms of depression or anxiety, but your data will remain entirely confidential. You will be 
assigned a code number so that your name is not associated with any of your data. If your 
responses suggest serious thoughts of suicide, we will arrange for you to speak with an available 
clinician or escort you to a nearby emergency room, if appropriate. You may benefit from taking 
part in this study, as we will provide you with some educational materials for coping with 
headaches, depression/anxiety, and HIV. Participants reporting significant symptoms of 
depression and anxiety will also be provided contact information for local mental health 
providers. There are no other benefits to participation. However, this study may help us better 
understand headache patterns and associated factors in individuals with HIV. 
 
Cost and Payments 
This study will take approximately 30-45 minutes of your time (15 minutes for the interview, 15-
30 minutes for the questionnaires), most of which will occur while you are waiting to see your 
doctor. There are no other costs for helping us with this study. 
 
Confidentiality 
We will not put your name on any of your tests. The only information that will be on your test 
materials will be your assigned code number. This code number will be linked to your name, 
your gender (whether you are male or female), your ethnicity, and your age. The list of code 
numbers will be kept at all times within a locked room and will be provided to no one other than 
the study personnel. The code list will be destroyed at the conclusion of the study. Any 
publications or presentations resulting from this study will not include any names or information 
that could lead to your identification. Therefore, we do not believe that you can be identified 
from any of your tests. 
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Right to Withdraw 
You do not have to take part in this study. If you start the study and decide that you do not want 
to finish, all you have to do is to tell your physician or the researchers. We want to assure you 
that whether or not you choose to participate or to withdraw will not affect your care at the 
clinic. No medical treatments will be added or withheld based on participation in this study. The 
researchers may terminate your participation in the study without regard to your consent and for 
any reason, such as protecting your safety and protecting the integrity of the research data. 
Protected Health Information 
Protected health information is any personal health information which identifies you in some 
way. The data collected in this study includes your age, date of HIV diagnosis, most recent CD4 
cell count and date taken, most recent viral load and date taken, sexual orientation, level of 
education, relationship status, a list of the medications you take, and other diagnoses. A 
decision to participate in this research means that you agree to the use of your health information 
for the study described in this form. This information will not be released beyond the purposes of 
conducting this study. The information collected for this study will be kept until the study is 
complete. While this study is ongoing you may not have access to the research information, but 
you may request it after the research is completed. 
 
IRB Approval 
This study has been reviewed by The University of Mississippi’s Institutional Review Board 
(IRB). The IRB has determined that this study fulfills the human research subject protections 
obligations required by state and federal law and University policies. If you have any questions, 
concerns, or reports regarding your rights as a participant of research, please contact the IRB at 
(662) 915-7482. 
Statement of Consent 
I have read the above information. I have been given a copy of this form. I have had an 
opportunity to ask questions, and I have received answers. I consent to participate in the study. 
  
Signature of Participant Date 
 
 
 
 
Signature of Investigator Date 
 
 
NOTE TO PARTICIPANTS:  DO NOT SIGN THIS FORM 
IF THE IRB APPROVAL STAMP ON THE FIRST PAGE HAS EXPIRED. 
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APPENDIX L: CONSENT TO RELEASE INFORMATION FROM MEDICAL RECORDS 
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                            Consent to Release Information from Medical Records  
 
            Investigator 
            Kale E. Kirkland, M.A. 
            Department of Psychology 
            302B Peabody Hall 
            The University of Mississippi 
            (334) 391-1719 
            Faculty Advisor 
            Todd A. Smitherman, Ph.D. 
            Department of Psychology 
  302D Peabody Hall 
     The University of Mississippi 
            (662) 915-1825 
 
Description 
Signing this form will authorize researchers to obtain specific information from your medical 
records: Age, date of HIV diagnosis, most recent CD4 cell count and date taken, most recent 
viral load and date taken, sexual orientation, level of education, relationship status, a list of the 
medications you take, and other diagnoses.  
 
Confidentiality 
Although the medical records used will be linked to your name, we will be recording medical 
data of interest on a demographic sheet that will not have identifiers or your name; you will 
instead be assigned a code number to ensure confidentiality. This code number will be linked to 
your name, your gender (whether you are male or female), your ethnicity, and your age. The list 
of code numbers will be kept at all times within a locked room and will be provided to no one 
other than the study personnel. The code list will be destroyed at the conclusion of the study. 
Any publications or presentations resulting from this study will not include any names or 
information that could lead to your identification. Therefore, we do not believe that you can be 
identified from any of your information. 
 
Protected Health Information 
Protected health information is any personal health information which identifies you in some 
way. The data collected in this study includes your age, date of HIV diagnosis, most recent CD4 
cell count and date taken, most recent viral load and date taken, sexual orientation, level of 
education, relationship status, a list of the medications you take, and other diagnoses. A 
decision to participate in this research means that you agree to the use of your health information 
for the study described in this form. This information will not be released beyond the purposes of 
conducting this study. The information collected for this study will be kept until the study is 
complete. While this study is ongoing you may not have access to the research information, but 
you may request it after the research is completed. 
 
IRB Approval 
This study has been reviewed by The University of Mississippi’s Institutional Review Board 
(IRB). The IRB has determined that this study fulfills the human research subject protections 
obligations required by state and federal law and University policies. If you have any questions, 
concerns, or reports regarding your rights as a participant of research, please contact the IRB at 
(662) 915-7482. 
Statement of Consent 
I have read the above information. I have been given a copy of this form. I have had an 
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opportunity to ask questions, and I have received answers. I consent to release information from 
my medical records as part of my participation in this study. 
  
Signature of Participant Date 
 
 
 
 
Signature of Investigator Date 
 
 
 
NOTE TO PARTICIPANTS:  DO NOT SIGN THIS FORM 
IF THE IRB APPROVAL STAMP ON THE FIRST PAGE HAS EXPIRED. 
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